

## VERZEICHNIS DER PUBLIKATIONEN

### Zeitschriftenbeiträge in reviewten Journalen

1. Haas, R., Hohaus, S., Goldschmidt, H., Witt, B., Hunstein, W. (1992) Autologous blood stem cell transplantation in Hodgkin's disease – the impact of rhG-CSF on blood stem cell collection. Bone Marrow Transplant. 10, Suppl. 2, 5-7
2. Haas, R., Ehrhardt, R., Witt, B., Goldschmidt, H., Hohaus, S., Pförsich, M., Ehrlich, H., Färber, L., Hunstein, W. (1993) Autografting with peripheral blood stem cells mobilized by sequential interleukin-3/granulocyte-macrophage colony-stimulation factor following high-dose chemotherapy in non-Hodgkin's lymphoma. Bone Marrow Transplant. 12, 643-649
3. Haas, H., Hohaus, S., Goldschmidt, H., Witt, B., Hunstein, W. (1993) Hematopoietic growth factors for the mobilization of peripheral blood stem cells. J Hematother. 2, 357-359
4. Hohaus, S., Goldschmidt, H., Ehrhardt, R., Haas, R. (1993) Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Exp Hematol. 21, 508-514
5. Frank, C., Flentje, M., Goldschmidt, H., Hunstein, W., Wannemacher, M. (1994) Results of radiotherapy and combined modality treatment in early stage, high-grade non-Hodgkin's lymphoma. Strahlenther Onkol. 170, 383-390
6. Haas, R., Hohaus, S., Goldschmidt, H., Möhle, R., Witt, B., Wannemacher, M., Hunstein, W. (1994) High-dose therapy and autografting with peripheral blood stem cells in malignant lymphoma: Granulocyte-macrophage colony-stimulating factor for stem cell mobilization. Sem Oncol. 21, Suppl. 16, 19-24
7. Haas R., Möhle, R., Murea S., Goldschmidt, H., Pförsich M., Witt, B., Hunstein W. (1994) Characterization of peripheral blood progenitor cells mobilized by cytotoxic chemotherapy and recombinant human granulocyte colony-stimulating factor. J Hematother. 3, 323-330
8. Haas, R., Möhle, R., Frühauf, S., Goldschmidt, H., Witt, B., Flentje, M., Wannemacher, M., Hunstein, W. (1994) Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood. 83, 3787-3794
9. Haas, R., Moos, M., Karcher, A., Möhle, R., Witt, B., Goldschmidt, H., Frühauf, S., Flentje, M., Wannemacher, M., Hunstein, W. (1994) Sequential high-dose therapy with peripheral blood progenitor cell support in low-grade non-Hodgkin lymphoma. J Clin Oncol. 12, 1685-1692
10. Krämer, A., Goldschmidt, H., Hahn, U., Andrassy, A. (1994) Progressive renal failure in two breast cancer patients after high-dose ifosfamide. Lancet. 344, No. 8936, 1569 (letter)
11. Dimitrakopoulou-Strauss, A., Strauss, L.G., Goldschmidt, H., Lorenz, W.J., Maier-Borst, W., van Kaick, G. (1995) Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Europ J Nucl Med. 22, 434-442
12. Goldschmidt, H., Hahn, U., Salwender, H.-J., Haas, R., Jansen, B., Wolbring, P., Rinck, M., Hunstein, W. (1995) Prevention of catheter related infections by silver coated central venous catheters in oncological patients. Zentralbl Bakteriol. 283, 215-223

13. Goldschmidt, H., Hegenbart, U., Moos, M., Wannemacher, M., Haas, R., Hunstein, W. (1995) Sequential high-dose treatment with peripheral blood progenitor cell transplantation in patients with multiple myeloma. *Stem Cells*. 13, Suppl. 3, 28-35
14. Haas, R., Möhle, R., Pförsich, M., Fruehauf, S., Witt, B., Goldschmidt, H., Hunstein, W. (1995) Blood-derived autografts collected during granulocyte colony-stimulating factor-enhanced recovery are enriched with early Thy-1+ hematopoietic progenitor cells. *Blood*. 85, 1936-1943
15. Haas, R., Moos, M., Karcher, A., Möhle, R., Witt, B., Goldschmidt, H., Flentje, M., Wannemacher, M., Hunstein, W. (1995) Sequential high-dose therapy in patients with low-malignancy non-Hodgkin's lymphoma. *Strahlenther Onkol*. 171, 300-301
16. Haas, R., Murea, S., Goldschmidt, H., Döhner, H., Moos, M., Witt, B., Hunstein, W. (1995) High-dose therapy with peripheral blood progenitor cell support (PBPC) in patients with non-Hodgkin's lymphoma. *Stem Cells*. 13, Suppl. 3, 28-35
17. Haas, R., Witt, B., Möhle, R., Goldschmidt, H., Hohaus, S., Frühauf, S., Wannemacher, M., Hunstein, W. (1995) Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor support. *Blood*. 85, 3754-3761
18. Hahn, U., Goldschmidt, H., Salwender, H.-J., Haas, R., Hunstein, W. (1995) Large bore, central venous catheters for the collection of peripheral blood stem cells. *J Clin Apheresis*. 10, 12-16
19. Hegenbart, U., Goldschmidt, H. (1995) Gastrointestinale Amyloidose bei IgG-k-Leichtketten-Plasmozytom. *Dtsch Med Wschr*. 120, 1187 (Leserzuschrift)
20. Goldschmidt, H., Haas, R., Hegenbart, U., Haas, R., Hunstein, W. (1996) Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m<sup>2</sup>) and granulocyte colony-stimulating factor (G-CSF) in patients with multiple myeloma (MM). *Bone Marrow Transplant*. 17, 691-697
21. Haas, R., Brittinger, G., Meusers, P., Murea, S., Goldschmidt, H., Wannemacher, M., Hunstein, W. (1996) Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. *Leukemia*. 10, 1975-1979
22. Haas, R., Moos, M., Möhle, R., Döhner, H., Witt, B., Goldschmidt, H., Murea, S., Flentje, M., Wannemacher, M., Hunstein, W. (1996) High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. *Bone Marrow Transplant*. 17, 149-155
23. Murea, S., Goldschmidt, H., Hahn, U., Pförsich, M., Moos, M., Haas, R. (1996) Successful collection and transplantation of peripheral blood stem cells in cancer patients using large-volume leukapheresis. *J Clin Apheresis*. 11, 185-196
24. Voso, M. T., Murea, S., Goldschmidt, H., Hohaus, S., Haas, R. (1996) High-dose therapy with peripheral blood stem cell transplantation results in a significant reduction of the hematopoietic progenitor cell compartment. *Br J Haematol*. 94, 759-766
25. Cremer, F.W., Kiel, K., Sucker, C., Wacker, J., Atzberger, A., Haas, R., Goldschmidt, H., Moos, M. (1997) A rationale for positive selection of peripheral blood stem cells in multiple myeloma: highly purified CD34+ cell fractions of leukapheresis products do not contain malignant cells. *Leukemia*. 11, Suppl. 5, 541-546
26. Cremer, F.W., Kiel, K., Wallmeier, M., Goldschmidt, H., Moos, M. (1997) A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myeloma. *Ann*

27. Dimitrakopoulou-Strauss, A., Strauss, L.G., Goldschmidt, H., Hegenbart, U., Irgartinger, G., Oberdorfer, F., van Kaick, G. (1997) Die Positronenemissionstomographie (PET) bei der Diagnostik und Therapieplanung von malignen Lymphomen. *Der Radiologe*. 37, 74-80
28. Egerer, G., Hegenbart, U., Salwender, H., Hahn, U., Haas, R., Goldschmidt, H., Hunstein, W. (1997) Ambulante Therapie des Multiplen Myeloms mit Vincristin, Adriamycin und Dexamethason (VAD). *Dtsch Med Wschr*. 122, 531-535
29. Goldschmidt, H., Hegenbart, U., Wallmeier, M., Engenhardt, R., Wannemacher, M., Haas, R. (1997) High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma (MM). *Ann Oncol*. 8, 1-4
30. Goldschmidt, H., Hegenbart, U., Wallmeier, M., Hohaus, S., Haas, R. (1997) Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. *Br J Haematol*. 98, 736-744
31. Goldschmidt, H., Hegenbart, U., Wallmeier, M., Moos, M., Haas, R. (1997) High-dose chemotherapy in multiple myeloma. *Leukemia*. 11, Suppl. 5, 527-531
32. Goldschmidt, H., Salwender, H., Egerer, G., Kempe, R., Voigt, T. (1997) Comparison of oral itasetron with oral ondansetron: Results of a double-blind, active-controlled phase II study in chemotherapy-naive patients receiving moderately-emetogenic chemotherapy. *Anti-Cancer Drugs*. 8, 436-444
33. Haas, R., Schmid, H., Hahn, U., Hohaus, S., Goldschmidt, H., Murea, S., Kaufmann, M., Wannemacher, M., Wallwiener, D., Bastert, G., Hunstein, W. (1997) Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk breast cancer. *Europ J Cancer*. 33, 372 - 378
34. Pfeiffer, S., Gooding, R., Apperley, J., Goldschmidt, H., Samson, D. (1997) Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors. *Br J Haematol*. 98, 973-982
35. Bellos, F., Ehrbrecht, E., Goldschmidt, H., Moos, M. (1998) Leukapheresis cells of patients with multiple myeloma collected after mobilisation with chemotherapy and G-CSF do not bear Kaposi's sarcoma-associated herpesvirus DNA. *Br J Haematol*. 103, 1192-1197
36. Cremer, W.F., Kiel, K., Wallmeier, M., Haas, R., Goldschmidt, H., Moos, M. (1998) Leukapheresis products in multiple myeloma: lower tumour load after mobilization with cyclophosphamide plus G-CSF compared to G-CSF alone. *Exp Hematol*. 26, 969-975
37. Huober, J., Schneeweiss, A., Hohaus, S., Wittmann, G., Meyer, A., Martin, S., Goldschmidt, H., Bastert, G., Haas, R., Wallwiener, D. (1998) Tandem and triple high-dose chemotherapy with autologous stem cell rescue in metastatic breast cancer. *J Cancer Res Clin Oncol*. 124, 690-694
38. Hohaus, S., Martin, H., Wassmann, B., Egerer, G., Haus, U., Färber, L., Burger, K.J., Goldschmidt, H., Hoelzer, D., Haas, R. (1998) Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. *Bone Marrow Transplant*. 22, 625-630

39. Kallmeyer, C., Wallmeier, M., Kiel, K., Moos, M., Hegenbart, U., Haas, R., Goldschmidt, H. (1998) Decreased numbers of circulating B cells in myeloma patients with reduction after conventional chemotherapy. *Am J Hematol.* 57, 287-292
40. Kiel, K., Cremer, F.W., Ehrbrecht, E., Wallmeier, M., Goldschmidt, H., Moos, M. (1998) First and second apharesis in patients with multiple myeloma: no differences in tumour load and hematopoietic stem cell yield. *Bone Marrow Transplant.* 21, 1109-1115
41. Martin-Murea, S., Voso, M.T., Hohaus, S., Pförsich, M., Fruehauf, S., Goldschmidt, H., Hegenbart, U., Haas, R. (1998) The dose of granulocyte-colony-stimulating factor (G-CSF) administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ hematopoietic progenitor cells during marrow recovery. *Br J Haematol.* 101, 582-585
42. Schönrich, G., Raftery, M., Schnitzler, P., Rohr, U., Goldschmidt, H. (1998) Absence of a correlation between Kaposi's associated herpesvirus (KSHV/HHV-8) and multiple myeloma. *Blood.* 92, 3474-3475 (letter)
43. Witzens, M., Egerer, G., Stahl, D., Werle, E., Goldschmidt, H., Haas, R. (1998) A case of  $\mu$  heavy-chain disease associated with hyperglobulinemia, anemia, and a positive Coombs test. *Ann Haematol.* 77, 431-434
44. Goldschmidt, H., Salwender H.-J., Hahn, U., Hegenbart, U., Egerer, G., Wallmeier, M., Jansen, B., Haas, R. (1998) Increased Risk of Catheter Colonization and Catheter-Related Infections in Severe Immunocompromized Patients with Multiple Myeloma Undergoing High-dose Glucocorticoid Treatment. *Zentralbl Bakteriol.* 287, 125-134
45. Goldschmidt, H., Hegenbart U., Wallmeier, M., Hohaus, S., Engenhardt, R., Wannemacher, M., Haas, R. (1998) Peripheral Blood Progenitor Cell Transplantation in Multiple Myeloma - Following High-dose Melphalan-base therapy. *Rec Res Cancer Res.* 144, 27-35
46. Bellos, F., Goldschmidt, H., Dörner, M., Ho, A.D., Moos, M. (1999) Bone marrow derived dendritic cells from patients with multiple myeloma cultured with three distinct protocols do not bear Kaposi's sarcoma associated herpesvirus DNA. *Ann Oncol.* 10, 323-327
47. Egerer, G., Goldschmidt, H., Streich, N., Ehrhardt, I., Sonntag, H. G., Haas, R (1999). Ceftazidime in combination with glycopeptide antibiotic is an effective first-line therapy for patients undergoing high-dose therapy with peripheral blood stem cell transplantation. *Support. Care Cancer.* 7, 336-342
48. Hohaus, S., Funk, L., Schlenk, R. F., Abdallah, A., Hahn, U., Egerer, G., Goldschmidt, H., Schneeweiß, A., Kaul, S., Wallwiener, D., Bastert, G., Haas, R. (1999) Stage III and oestrogen receptor negative are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer. *Br J Cancer.* 79, 1500-1507
49. Kiel, K., Cremer, F.W., Rottenburger, C., Kallmeyer, C., Ehrbrecht, E., Atzberger, A., Hegenbart, U., Goldschmidt, H., Moos, M. (1999) Analysis of circulating tumour cells in patients with multiple myeloma in the course of high-dose therapy with peripheral blood stem cell transplantation. *Bone Marrow Transplant.* 23, 1019-1027
50. Mantaka, P., Dimitrakopoulou-Strauss, A., Strauss, L.G., Moehler, M., Goldschmidt, H., Oberdorfer, F., Kontaxakis, G., van Kaick, G. (1999) Detection of treated liver metastases using fluorine-18-fluorodeoxyglucose (FDG) and positronemissiontomography (PET). *Anticancer Res.* 19, 4443-4450

51. Rottenburger, Ch., Kiel, K., Boesing, Th., Cremer, F.W., Moldenhauer, G., Ho, A.D., Goldschmidt, H., Moos, M. (1999) Clonotypic CD20 and CD19 B-cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation. *Br J Haematol.* 106, 545-552
52. Schultheis, B., Krämer, A., Willer, A., Hegenbart, U., Goldschmidt, H., Hehlmann, R. (1999) Analysis of p73 and p53 gene deletions in multiple myeloma. *Leukemia.* 13, 2099-2103
53. Voso, M.T., Hohaus, S., Moos, M., Pförsich, M., Cremer, F.W., Schlenk, R.F., Martin, S., Hegenbart, U., Goldschmidt, H., Haas, R. (1999) Autografting with CD34+ peripheral blood stem cells (PBSC): retained engraftment capability and reduced tumor cell content. *Br J Haematol.* 104, 382-391
54. Bösing, T., Bellos, F., Cremer, F.W., Moldenhauer, G., Ho, A.D., Goldschmidt, H., Moos, M. (2000) CD19<sup>+</sup> and CD20<sup>+</sup> B-cells from the peripheral blood of patients with multiple myeloma are not infected with human herpesvirus 8. *Leukemia.* 14, 1330-1331
55. Cremer, F.W., Ehrbrecht, E., Kiel, K., Benner, A., Hegenbart, U., Ho, A.D., Goldschmidt, H., Moos, M. (2000) Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma. *Bone Marrow Transplant.* 26, 851-858
56. Cremer, F.W., Goldschmidt, H. (2000) Multiple myeloma - current concepts for an interdisciplinary management. *J Cancer Res Clin Oncol.* 126, 119-123
57. Neben, K., Hohaus, S., Goldschmidt, H., Egerer, G., Voso, M.T., Ho, A.D., Haas, R. (2000) High-dose therapy with peripheral blood stem cell (PBSC) transplantation for patients with relapsed or refractory Hodgkin's disease: long-term outcome and prognostic factors. *Ann Haematol.* 79, 547-555
58. Waldmann, V., Goldschmidt, H., Jaeckel, A., Deichmann, M., Hegenbart, U., Hartschuh, W., Ho, A.D. Näher, H. (2000) Rapid relapse after complete remission of metastasized merkel cell carcinoma by high-dose polychemotherapy and autologous bone marrow transplantation. *Br J Dermatol.* 143, 837-839
59. Egerer, G., Goldschmidt, H., Salwender, H., Hegenbart, U., Ehrhard, I., Haas, R., Ho, A. (2000) Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after high-dose chemotherapy and peripheral blood stem cell transplantation. *Int J of Antimicrobial Agents.* 15, 119-123
60. Abdallah, A., Egerer, G., Goldschmidt, H., Wannemacher, M., Körbling, M., Ho, A. (2001) Continuous complete remission in adult patients with acute lymphocytic leukaemia at a median observation of 12 years after autologous bone marrow transplantation. *Br J Haematol.* 112, 1012-1015
61. Björkstrand, B., Svensson, H., Goldschmidt, H., Ljungman, P., Apperley, J., Mandelli, F., Marcus, R., Boogaerts, M., Alegre, A., Remes, K., Cornelissen, J.J., Blade, J., Lenhoff, S., Iriando, A., Carlson, K., Sweetenham, J., Volin, L., Littlewood, T., Goldstone, A.H., Miguel, J. S., de Witte, T., Gahrton, G. (2001) Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation: A retrospective registry study from the european group for blood and bone marrow transplantation (EBMT). *Bone Marrow Transplant.* 27, 511-515
62. Cremer, F.W., Goldschmidt, H., Moos, M. (2001) Clonotypic B cells in the peripheral

blood of patients with multiple myeloma. *Blood*. 97, 2913-2914 (letter)

63. Egerer, G., Goldschmidt, H., Mueller, I., Karthaus, M., Guenther, H., Ho, A.D. (2001) Ceftriaxone for the treatment of febrile episodes in patients with hemato-oncological disease or HIV-infection: comparison of outpatient and inpatient care. *Chemotherapy*. 47, 219-225
64. Egerer, G., Hegenbart, U., Salwender, H., Hahn, U., Schmier, J. W., Haas, R., Ho, A.D., Goldschmidt, H. (2001) Outpatient treatment of multiple myeloma with a combination of vincristine, adriamycin and dexamethasone (VAD). *Support Care Cancer*. 9, 380-385
65. Egerer, G., Witzens, M., Spaeth, A., Breitbart, A., Möller, P., Goldschmidt, H., Ho, A.D. (2001) Successful treatment of bronchiolitis obliterans organizing pneumonia with low-dose methotrexate in a patient with Hodgkin's disease. *Oncology*. 61, 23-27
66. Lipinski, E., Cremer, F., Ho, A.D., Goldschmidt, H., Moos, M. (2001) Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high dose therapy with autologous blood stem cell transplantation. *Bone Marrow Transplant*. 28, 957-962
67. Moehler, T.M., Hawighorst, H., Neben, K., Egerer, G., Hillengass, J., Max, R., Benner, A., van Kaick, G., Ho, A.D., Goldschmidt, H. (2001) Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging. *Int J Cancer*. 93, 862-869
68. Moehler, T.M., Neben, K., Benner, A., Egerer, G., Krasniqi, F., Ho, A.D., Goldschmidt, H. (2001) Salvage therapy for multiple myeloma with thalidomide and CED-chemotherapy. *Blood*. 98, 3846-3848
69. Neben, K., Moehler, T., Egerer, G., Kraemer, A., Hillengass, J., Benner, A., Ho, A.D., Goldschmidt, H. (2001) High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. *Clin Cancer Res*. 7, 2675-2681
70. Neben, K., Moehler, T., Kraemer, A., Benner, A., Egerer, G., Ho, A.D., Goldschmidt, H. (2001) Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. *Br J Haematol*. 115, 605-608
71. Stahl, D., Egerer, G., Goldschmidt, H., Sibrowski, W., Kazatchkine, M.D., Kaveri, S.V. (2001) Altered self-reactive antibody repertoires are a general feature of patients with myelo-dysplastic syndrome. *J Autoimmunity*. 16, 77-86
72. Egerer, G., Goldschmidt, H., Hensel, M., Harter, C., Schneeweiß, A., Ehrhard, R., Bastert, G., Ho, A.D. (2002) Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation. *Bone Marrow Transplant*. 30, 427-431
73. Harter, C., Salwender, H.J., Bach, A., Egerer, G., Goldschmidt, H., Ho, A.D. (2002) Catheter-related thrombosis of the internal jugular vein in hematological patients undergoing chemotherapy: a prospective comparison of silver-coated and uncoated catheters. *Cancer*. 94, 245-251
74. Hensel, M., Egerer, G., Schneeweiß, A., Goldschmidt, H., Ho, A.D. (2002) Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation. *Ann Oncol*. 13, 209-213
75. Gemmel, C., Cremer, F.W., Weis, M., Witzens, M., Moldenhauer, G., Koniczek, K.,

- Imbach, U., Ho, A.D., Moos, M., Goldschmidt, H. (2002). Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous transplantation. *Ann Haematol.* 81, 119-123
76. Goerner, M., Kordelas, L., Luft, T., Pfeiffer, S., Punzel, M., Weber-Nordt, R., Moos, M., Goldschmidt, H., Ho, A.D. (2002) Stable mixed chimerism after T cell-depleted allogeneic hematopoietic stem cell transplantation using conditioning with low dose total body irradiation and fludarabine. *Bone Marrow Transplant.* 29, 621-624
77. Krämer, A., Schultheis, B., Bergmann, J., Willer, A., Hegenbart, U., Ho, A.D., Goldschmidt, H., Hehlmann, R. (2002) Alterations of the cyclin D1/pRb/p16Ink4 pathway in multiple myeloma. *Leukemia.* 16, 1844-1851
78. Neben, K., Moehler, T., Benner, A., Kraemer, A., Egerer, G., Ho, A.D., Goldschmidt, H. (2002) Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. *Clin Cancer Res.* 8, 3377-3382
79. Neben, K., Mytilineos, J., Moehler, T., Preis, A., Kraemer, A., Ho, A.D., Opelz, G., Goldschmidt, H. (2002) Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for the outcome after thalidomide therapy in relapsed and refractory multiple myeloma. *Blood.* 100, 2263-2265
80. Egerer, G., Goldschmidt, H., Zoz, M., Ho, A.D. (2003) Autologous bone marrow transplantation in adult patients with acute lymphoblastic leukaemia. *Leukaemia and Lymphoma.* 44, 9-14
81. Moehler, T.M., Ho, A.D., Goldschmidt, H., Barlogie, B. (2003) Angiogenesis in hematologic malignancies. *Critical Rev Oncol/Hematol.* 45, 227-244
82. Streitberger, K., Friedrich-Rust, M., Bardenheuer, H., Unnebrink, K., Windeler, J., Goldschmidt, H., Egerer, G. (2003) Effect of acupuncture compared with placebo-acupuncture at P6 as additional antiemetic prophylaxis in high-dose chemotherapy and autologous peripheral blood stem cell transplantation: A randomized controlled single-blind trial. *Clin Cancer Res.* 9, 2538-2544
83. Liebisch, P., Viardot, A., Bassermann, N., Wendl, C., Roth, K., Goldschmidt, H., Einsele, H., Straka, C., Stilgenbauer, S., Döhner, H. Bentz, M. (2003) Value of comparative genomic hybridization and fluorescence in situ hybridisation for molecular diagnostics in multiple myeloma. *Br J Haematol.* 122, 193-201
84. Harter, C., Egerer, G., Goldschmidt, H., Ho, A.D. (2003) Peripherally inserted central venous catheters for autologous blood progenitor cell transplantation in patients with haematological malignancies. *Support Care Cancer.* 11, 790-794
85. Zeier, M., Perz, J., Linke, R.P., Donini, U., Waldherr, R., Andrassy, K., Ho, A.D., Goldschmidt, H. (2003) No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement. *Nephrol Dial Transplant.* 18, 2644-2647
86. Luft, T., Moos, M., Goldschmidt, H., Ho, A.D., Goerner, M. (2003) Dissociation of putative graft-versus-hematopoiesis and graft-versus-myeloma effects in patients with rapidly progressive multiple myeloma. *Br J Haematol.* 123, 646-653
87. Liebisch, P., Wendl, C., Wellmann, A., Roth, K., Janczik, S., Kröber, A., Schilling, G., Goldschmidt, H., Einsele, H., Bentz, M., Stilgenbauer, S., Döhner, H. (2003) High incidence of trisomies 1q, 9q, and 11q in multiple myeloma - Results from a comprehensive molecular cytogenetic analysis. *Leukemia.* 17, 2535-2537

88. Seggewiss, R. Buss, E. C., Herrmann, D., Goldschmidt, H., Ho, A.D., Fruehauf, S. (2003) Kinetics of peripheral blood stem cell mobilization following G-CSF supported chemotherapy. *Stem cells*. 21, 568-574
89. Kasper, B., Moehler, T., Neben, K., Ho, A.D., Goldschmidt, H. (2004) Combination therapy of Thalidomide and Peginterferon in patients with progressive multiple myeloma. *Ann Oncol*. 15, 176-177
90. Hug, A., Storch-Hagenlocher, B., Haas, J., Vogt-Schaden, M.-E., Goldschmidt, H., Wildemann, B. (2004) Single cell PCR analysis of the immunoglobulin heavy chain CDR3 region for the diagnosis of leptomeningeal B-cell malignancies using standard cerebrospinal fluid cytopins. *J Neurol Sci*. 219, 83-88
91. Glasmacher, A., Goldschmidt, H., Mezger, J., Haferlach, T., Schmidt-Wolf, I.G.H., Gieseler, F. (2004) Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma: Final analysis of a phase II trial. *Haematologica*. 89, 371-373
92. Witzens, M., Moehler, T., Fruehauf, S., Hartschuh, W., Ho, A.D., Goldschmidt, H. (2004) Development of leucocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide. *Ann Haematol*. 83, 467-470
93. Kasper, B., Lehnert, Th, Bernd, L., Mechtersheimer, G., Goldschmidt, H., Ho, A.D., Egerer, G. (2004) High-dose chemotherapy with autologous peripheral stem cell transplantation for bone and soft-tissue sarcomas. *Bone Marrow Transplant*. 34, 1-5
94. Bakkus, M.H., Bouko, Y., Samson, D., Apperley, J.F., Thielemans, K., Van Camp, B., Benner, A., Goldschmidt, H., Moos, M., Cremer, F.W. (2004) Post-transplantation tumour load in bone marrow assessed by quantitative ASO-PCR is a prognostic parameter in multiple myeloma. *Br J Haematol*. 126, 665-674
95. Wasser, K., Moehler, T., Neben, K., Nosas, S., Heiss, J., Goldschmidt, H., Hillengass, J., Duber, C., Kauczor, H.U., Delorme, S. (2004) Dynamisches MRT des Knochenmarks zum Monitoring des Multiplen Myeloms unter Thalidomid-Monotherapie oder in Kombination mit CED-Therapie. *Rofo*. 176, 1285-1295
96. Perz, J., Schonland, S.O., Hundemer, M., Kristen, A., Dengler, T., Zeier, M., Linke, R., Ho, A.D., Goldschmidt, H. (2004) High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of AL amyloidosis: a single centre prospective phase II study. *Br J Haematol*. 127, 543-551
97. Minnema, M.C., Breitzkreutz, I., Auwerda, J.J.A., van der Holt, B., Cremer, F.W., van Marion A.M.W., Westveer, P.H.M., Sonneveld, P., Goldschmidt, H., Lokhorst, H.M. (2004) Prevention of venous thrombo-embolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. *Leukemia*. 18, 2044-2046
98. Schlenzka, J., Moehler, T.M., Kipriyanov, S.M., Benner, A., Kornacker, M., Bähre, A., Stassar, M.J., Schäfer, H.J., Little, M., Goldschmidt, H., Cochlovius, B. (2004) Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a pre-clinical model of human B cell lymphoma. *Anticancer Drugs*. 15, 915-919
99. Choi, C., Witzens, M., Bucur, M., Feuerer, M., Sommerfeld, T., Trojan, A., Ho, A.D., Schirrmacher, V., Goldschmidt, H., Beckhove, P. (2005) Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of multiple myeloma patients. *Blood*. 105, 2132-2134

100. Liebisch, P., Scheck, D., Ern , S. A., Wellmann, A., Wendl, C., Janczik, S., Kolmus, S., Kr ber, A., Goldschmidt, H., Einsele, H., Straka, H., Benner, A., Stilgenbauer, S., D hner, H. (2005) Duplication of chromosome arms 9q and 11q a novel, translocation-independent pathogenetic pathway in multiple myeloma. *Genes Chromosomes Cancer*. 42, 78-81
101. Cremer, F.W., Bouko, Y., Samson, D., Apperley, J.F., Thielemans, K., Van Camp, B., Benner, A., Goldschmidt, H., Moos, M., Bakkus, M.H. (2005) Post-transplantation tumour load in bone marrow assessed by quantitative ASO-PCR is a prognostic parameter in multiple myeloma. Response to Owen and Rawstron. *Br J Haematol*. 128, 733-734
102. Mahtouk, K., Hose, D., R me, T., De Vos, J., Jourdan, M., Moreaux, J., Fiol, G., Raab, M., Jourdan, E., Grau, V., Moos, M., Goldschmidt, H., Rossi, J.F., Cremer, F.W., Klein, B. (2005) Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. *Oncogene*. 12, 3512-3524
103. Zeifang, F., Zahlten-Hinguranage, A., Goldschmidt, H., Cremer, F., Bernd L., Sabo, D. (2005) Long-term survival after surgical intervention for bone disease in multiple myeloma. *Ann Oncol*. 16, 222-227
104. Raab, M.S., Cremer, F.W., Gerull, S., Luft, T., Benner, A., Goerner, M., Ho, A.D., Goldschmidt, H., Moos, M. (2005) Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma. *Ann Oncol*. 16, 611-617
105. Moreaux, J., Cremer, F.W., Reme, T., Raab, M., Mahtouk, K., Theil, A.C., Pantesco, V., De Vos, J., Jourdan, E., Jauch, A., Legouffe, E., Moos, M., Fiol, G., Goldschmidt, H., Rossi, J.F., Hose, D., Klein, B. (2005) The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. *Blood*. 106, 1021-1030
106. Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Blad , J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Schenkein, D., Anderson, K.C. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. *N Engl J Med*. 352, 2487-2498
107. Nos s-Garcia, S., Moehler, T., Wasser, K., Kiessling, F., Bartl, R., Zuna, I., Hillengass, J., Goldschmidt, H., Delorme, S. (2005) Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: a comparative study with histology and clinical markers. *J Magn Reson Imaging*. 22, 154-162
108. Ostendorf, T., Meinhold, A., Harter, C., Salwender, H., Egerer, G., Geiss, H.K., Ho, A.D., Goldschmidt, H. (2005) Chlorhexidine and silver-sulfadiazine coated central venous catheters in haematological patients. *Support Care Cancer*. 13, 993-1000
109. Cremer, F.W., Kartal, M., Hose, D., Bila, J., Buck, I., Bellos, F., Raab, M.-S., Brough, M., Moebus, A., Hager, H.-D., Goldschmidt, H., Moos, M., Bartram, C.R., Jauch, A. (2005) High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISH. *Cancer Genetics Cytogenetics*. 161, 116-124
110. Lotz, C., Mutallib, S.A., Liewer, U., Ferreira, E.A., Moos, M., Hundemer, M., Schneider, S., Strand, S., Huber, C., Goldschmidt, H., Theobald, M. (2005) Targeting PRDI-BF1 and XBP-1 transcription factors by multiple myeloma-reactive CTL. *J Immunol*. 175, 1301-1309

111. Cremer, F.W., Bila, J., Buck, I., Kartal, M., Hose D., Ittrich, C., Benner, A., Raab, M.-S., Theil, A., Moos, M., Goldschmidt, H., Bartram, C.R., Jauch, A. (2005) Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase- cytogenetics. *Genes Chromosomes Cancer*. 44, 194-203
112. Gerull, S., Goerner, M., Benner, A., Hegenbart, U., Klein, U., Schaefer, H. J., Goldschmidt, H., Ho, A.D. (2005) Long-term outcome of non-myeloablative allogeneic transplantation in patients with high risk multiple myeloma. *Bone Marrow Transplant*. 36, 963-969
113. van de Donk, N.W., Kroeger, N., Hegenbart, U., Corradini, P., San Miguel, J.F., Goldschmidt, H., Perez-Simon, J.A., Zijlmans, M., Raymakers, R.A., Montefusco, V., Ayuk, F.A., van Oers, M.H., Nagler, A., Verdonck, L.F., Lokhorst, H.M. (2006) Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. *Bone Marrow Transplant*. 37, 1135-1141
114. Schonland, S., Lokhorst, H., Buzyn, A., Hegenbart, U., Bandini, G., Campbell, A., Carreras, E., Ferrant, A., Grommisch, L., Jacobs, P., Kroger, N., La Nasa, G., Leblond, V., Russell, N., Zachee, P., Goldschmidt, H., Iacobelli, S., Niederwieser, D., Gahrton, G. (2006) Allogeneic and syngeneic hematopoietic transplantation in patients with AL-amyloidosis: A report from the European Group for Blood and Marrow Transplantation (EBMT). *Blood*. 107, 2578-2584
115. Glasmacher, A., Hahn, C., Hoffmann, F., Naumann, R., Goldschmidt, H., von Lilienfeld-Toal, M., Orlopp, K., Schmidt-Wolf, I., Gorschlüter, M. (2006) A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. *Brit J Haematol*. 132, 584-593
116. Harter, Ch., Schulze, B., Goldschmidt, H., Benner, A., Geiss, H. K., Hoppe-Tichy, T., Ho, A.D., Egerer, G. (2006) Piperacillin/Tazobactam versus Ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: A prospective randomized trial. *Bone Marrow Transplant*. 37, 373-379
117. van de Donk, N.W., Kröger, N., Hegenbart, U., Corradini, P., San Miguel, J.F., Goldschmidt, H., Perez-Simon, J.A., Zijlmans, M., Raymakers, R.A. Montefusco, V., Ayuk, F.A., van Oers, M.H., Nagler, A., Verdonck, L.F., Lokhorst, H.M. (2006) Remarkable activity of novel agents Bortezomib and Thalidomide on patients not responding to donor lymphocyte infusion following allogeneic stem cell transplantation in multiple myeloma. *Blood*. 107, 3415-3416
118. Heß, T., Egerer, G., Moehler, T., Kasper, B., Rasul, K.I., Goldschmidt, H., Kauffmann, G.W. (2006) Atypical manifestations of multiple myeloma: Radiological appearance. *Europ J Radiol*. 58, 280-285
119. Hundemer, M., Schmidt, S., Condomines, M., Lupu, A., Hose, D., Moos, M., Cremer, F., Kleist, C., Terness, P., Belle, S., Ho, A.D., Goldschmidt, H., Klein, B., Christensen, O. (2006) Identification of a new HLA-A2-restricted T-cell-epitope within HM1.24 as immunotherapy target for multiple myeloma. *Exp Hematol*. 34, 486-496
120. Trojan, A., Tinguely, M., Vallet, S., Seifert, B., Jenni, B., Zippelius, A., Witzens-Harig, M., Mechtersheimer, G., Ho, A.D., Goldschmidt, H., Jäger, D., Boccadoro, M., Ladetto, M. (2006) Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma. *Swiss Med Weekly*. 136, 400-403

121. Schmidt-Wolf, I.G., Glasmacher, A., Hahn-Ast, C., Jüttner, A., Schnurr, T., Cremer, F., Moehler, T., Goldschmidt, H., Busert, B., Schubert, R., Schwanitz, G. (2006) Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance. *Cancer Genet Cytogenet.* 167, 20-25
122. Li, G., Hundemer, M., Wolfrum, S., Ho, A.D., Goldschmidt, H., Witzens-Harig, M. (2006) Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A). *Ann Hematol.* 85, 583-590
123. Fruehauf, S., Seeger, T., Maier, P., Li, L., Weinhardt, S., Laufs, S., Wagner, W., Eckstein, V., Bridger, G., Calandra, G., Wenz, F., Zeller, W.J., Goldschmidt, H., Ho, A.D. (2006) The CXCR4 antagonist AMD3100 releases a subset of G-CSF primed peripheral blood progenitor cells with specific gene expression characteristics. *Exp Hematol.* 34, 1052-1059
124. Mahtouk, K., Cremer, F.W., Reme, R., Jourdan, M., Baudard, M., Moreaux, J., Requirand, G., Fiol, G., De Vos, J., Moos, M., Quittet, P., Goldschmidt, H., Rossi, J.F., Hose, D., Klein, B. (2006) Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. *Oncogene.* 25, 7180-7191
125. Moreaux, J., Hose, D., Reme, T., Jourdan, E., Hundemer, M., Legouffe, E., Moine, P., Bourin, P., Moos, M., Corre, J., Moehler, T., De Vos, J., Rossi, J.F., Goldschmidt, H., Klein, B. (2006) CD200 is a new prognostic factor in multiple myeloma. *Blood.* 108, 4194-4197
126. Anagnostopoulos, A., Hari, P.N., Perez, W.S., Ballen, K., Bashey, A., Bredeson C.N., Freytes, C.O., Gale, R.P., Gertz, M.A., Gibson, J., Goldschmidt, H., Lazarus, H.M., McCarthy, P.L., Reece, D.E., Vesole, D.H., Giralt, S.A. (2006) Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. *Biol Blood Marrow Transplant.* 12, 845-854
127. Raab, M.S., Breitkreutz, I., Hundemer, M., Benner, A., Klaus, J., Hegenbart, U., Moehler, T., Ho, A.D., Zeier, M., Goldschmidt, H. (2006) The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure. *Haematologica.* 91, 1555-1558
128. Zahlten-Hinguranage, A., Goldschmidt, H., Cremer, F.W., Egerer, G., Moehler, T., Witte, D., Bernd, L., Sabo, D., Zeifang, F. (2006) Preoperative elevation of serum C-reactive protein is predictive for prognosis in myeloma bone disease after surgery. *Br J Cancer.* 95, 782-787
129. Klaus, J., Herrmann, D., Breitkreutz, I., Hegenbart, U., Mazitschek, U., Egerer, G., Cremer F.W., Lowenthal, R. M., Huesing, J., Fruehauf, S., Moehler, T., Ho, A.D., Goldschmidt, H. (2006) Effect of CD34+ cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma (MM) undergoing autologous peripheral blood stem cell (PBSC) transplantation. *Eur J Haematol.* 78, 21-28
130. Condomines, M., Hose, D., Raynaud, P., Hundemer, M., De Vos, J., Baudard, M., Moehler, T., Pantesco, V., Moos, M., Schved, J.F., Rossi, J.F., Reme, T., Goldschmidt, H., Klein, B. (2007) Cancer/Testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. *J Immunol.* 178, 3307-3315
131. Hillengass, J., Wasser, K., Delorme, S., Kiessling, F., Zechmann, C., Benner, A., Kauczor, H.U., Ho, A.D. Goldschmidt, H., Moehler, T.M. (2007) Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance

imaging is a predictor of event-free survival in progressive multiple myeloma. Clin. Cancer Res. 13, 475-481

132. Mahtouk, K., Hose, D., Raynaud, P., Hundemer, M., Jourdan, M., Jourdan, E., Pantesco, V., Baudard, M., De Vos, J., Larroque, M., Moehler, T., Rossi, J.F., Reme, T., Goldschmidt, H., Klein, B. (2007) Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood. 109, 4914-4923
133. Bretkreutz, I., Lokhorst, H.M., Raab, M.S., Holt, B.V., Cremer, F.W., Herrmann, D., Glasmacher, A., Schmidt-Wolf, I.G., Blau, I.W., Martin, H., Salwender, H., Haenel, A., Sonneveld, P., Goldschmidt, H. (2007) Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia. 21, 1294-1299
134. Moreaux, J., Hose, D., Jourdan, M., Reme, T., Hundemer, M., Moos, M., Robert, N., Moine, P., DeVos, J., Goldschmidt, H., Klein, B. (2007) TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines. Haematologica 92, 803-811
135. Kristen, A.V., Perz, J.B., Schonland, S.O., Hegenbart, U., Schnabel, P.A., Kristen, J.H., Goldschmidt, H., Katus, H.A., Dengler, T.J. (2007) Non-invasive predictors of survival in cardiac amyloidosis. Eur J Heart Fail. 9, 617-624
136. Fruehauf, S., Klaus, J., Huesing, J., Veldwijk, M.R., Buss, E.C., Topaly, J., Seeger, T., Zeller, L.W., Moehler, T., Ho, A.D., Goldschmidt, H. (2007) Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant. 39, 743-750
137. Jourdan, M., Moreaux, J., Vos, J.D., Hose, D., Mahtouk, K., Abouladze, M., Robert, N., Baudard, M., Reme, T., Romanelli, A., Goldschmidt, H., Rossi, J.F., Dreano, M., Klein, B. (2007) Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth. Br J Haematol. 138, 160-168
138. Witzens-Harig, M., Waldherr, R., Beimler, J., Zeier, M., Hansmann, J., Ho, A.D., Goldschmidt, H., Moehler, T. (2007) Long-term remission of paraprotein-induced immunotactoid glomerulopathy after high-dose therapy and autologous blood stem cell transplantation. Ann Hematol. 86, 927-930
139. Bourhis, J.H., Bouko, Y., Koscielny, S., Bakkus, M., Greinix, H., Derigs, G., Salles, G., Feremans, W., Apperley, J., Samson, D., Niederwieser, D., Gahrton, G., Pico, J.L., Goldschmidt H. (2007) Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study. Haematologica. 92, 1083-1090
140. Richardson, P.G., Sonneveld, P., Schuster, M., Irwin, D., Stadtmauer, E., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San Miguel, J., Blade, J., Boccadoro, M., Cavenagh, J., Alsina, M., Rajkumar, S.V., Lacy, M., Jakubowiak, A., Dalton, W., Boral, A., Esseltine, D.L., Schenkein, D., Anderson, K.C. (2007) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 110, 3557-3560
141. Hundemer, M., Klein, U., Hose, D., Raab, M.S., Cremer, F.W., Jauch, A., Benner, A., Heiss, C. Moos, M. Ho, A.D., Goldschmidt, H. (2007) Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Bone Marrow Transplant. 40,

142. Kristen, A.V., Perz, J.B., Schonland, S.O., Hansen, A., Hegenbart, U., Sack, F.U., Goldschmidt, H., Katus, H.A., Dengler, T.J. (2007) Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis. *J Heart Lung Transplant.* 26, 1313-1319
143. Sack, F.U., Kristen, A., Goldschmidt, H., Schnabel, P.A., Dengler, T., Koch, A., Karck, M. (2007) Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. *Eur J Cardiothorac Surg.* 33, 257-262
144. Mahtouk, K., Hose, D., De Vos, J., Moreaux, J., Jourdan, M., Rossi, J.F., Rème, T., Goldschmidt, H., Klein, B. (2007) Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications. *Clin Cancer Res.* 13, 7289-7295
145. Lokhorst, H.M., Schmidt-Wolf, I., Sonneveld, P., van der Holt, B., Martin, H., Barge, R., Bertsch, U., Schlenzka, J., Bos, G.M., Croockewit, S., Zweegman, S., Breitkreutz, I., Joosten, P., Scheid, C., van Marwijk-Kooy, M., Salwender, H.J., van Oers, M.H., Schaafsma, R., Naumann, R., Sinnige, H., Blau, I., Verhoef, G., de Weerd, O., Wijermans, P., Wittebol, S., Duersen, U., Vellenga, E., Goldschmidt, H.; Dutch-Belgian HOVON; German GMMG (2008) Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. *Haematologica.* 93, 124-127
146. Moehler, T.M., Sauer, S., Witzel, M., Andrulis, M., Garcia-Vallejo, J.J., Grobholz, R., Willhauck-Fleckenstein, M., Greiner, A., Goldschmidt, H., Schwartz-Albiez, R. (2008) Involvement of alpha 1-2-fucosyltransferase I (FUT1) and surface-expressed lewis(y) (CD174) in first endothelial cell-cell contacts during angiogenesis. *J Cell Physiol.* 215, 27-36
147. San-Miguel, J.F., Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., Bladé, J., Boccadoro, M., Cavenagh, J.D., Neuwirth, R., Boral, A.L., Esseltine, D.L., Anderson, K.C. (2008) Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. *Leukemia.* 22, 842-849
148. Reme, T., Hose, D., De Vos, J., Vassal, A., Poulain, P.O., Pantesco, V., Goldschmidt, H., Klein, B. (2008) A new method for class prediction based on signed-rank algorithms applied to Affymetrix(R) microarray experiment. *BMC Bioinformatics.* 9, 16
149. Bochtler, T., Hegenbart, U., Cremer F.W., Heiss, C., Benner, A., Hose, D., Moos, M., Bila, J., Bartram, C.R., Ho, A.D. Goldschmidt, H., Jauch, A., Schonland, S.O. (2008) Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared to monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. *Blood.* 111, 4700-4705
150. Bochtler, T., Hegenbart, U., Heiss, C., Brenner, A., Cremer, F., Volkmann, M., Ludwig, J., Perz, J.B., Ho, A.D., Goldschmidt, H., Schonland, S.O. (2008) Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. *Haematologica.* 93, 459-462

151. Kristen, A.V., Dengler, T.J., Hegenbart, U., Schonland, S.O., Goldschmidt, H., Sack, F.U., Voss, F., Becker, R., Katus, H.A., Bauer, A. (2008) Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. *Heart Rhythm*. 5, 235-240
152. Schmitt, S., Mailaender, V., Egerer, G., Leo, A., Becker, S., Reinhardt, P., Wiesneth, M., Schrezenmeier, H., Ho, A.D., Goldschmidt, H., Moehler, T.M. (2008) Successful autologous peripheral blood stem cell transplantation in a Jehovah's Witness with multiple myeloma: review of literature and recommendations for high-dose chemotherapy without support of allogeneic blood products. *Int J Hematol*. 87, 289-297
153. Hillengass, J., Zechmann, C.M., Nadler, A., Hose, D., Cremer, F.W., Jauch, A., Heiss, C., Benner, A., Ho, A.D., Bartram, C.R., Kauczor, H.U., Delorme, S., Goldschmidt, H., Moehler, T.M. (2008) Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma. *Int J Cancer*. 122, 2871-2875
154. Belle, S., Han, F., Condomines, M., Christensen, O., Witzens-Harig, M., Kasper, B., Kleist, C., Terness, P., Moos, M., Cremer, F., Hose, D., Ho, A.D., Goldschmidt, H., Klein, B., Hundemer, M. (2008) Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma. *Eur J Haematol*. 81, 26-35
155. Frank, C., Hundemer, M., Ho, A.D., Goldschmidt, H., Witzens-Harig, M. (2008) Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myeloma. *Leuk Lymphoma*. 49, 779-785
156. Schonland S.O., Hansmann J., Mechttersheimer G., Goldschmidt, H., Ho A.D., Hegenbart U. (2008) Bone involvement in patients with systemic AL amyloidosis mimics lytic myeloma bone disease. *Haematologica*. 93, 955-956
157. Klein, U., Kosely, F., Hillengass, J., Hundemer, M., Schmitt, S., Neben, K., Moehler, T., Hegenbart, U., Ho, A.D., Goldschmidt, H. (2008) Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. *Ann Hematol*. 88, 67-71
158. Chanan-Khan, A., Sonneveld, P., Schuster, M.W., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yahuda, D., Lonial, S., Goldschmidt, H., Reece, D., Neuwirth, R., Anderson, K.C., Richardson, P.G. (2008) Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. *J Clin Oncol*. 26, 4784-4790
159. Pönisch, W., Rozanski, M., Goldschmidt, H., Hoffmann F.A., Boldt, T., Schwarzer, A., Ritter, U., Rohrberg, R., Schwalbe, E., Uhlig, J., Zehrfeld, T., Schirmer, V., Haas, A., Kreibich, U., Niederwieser, D., for the East German Study Group of Haematology and Oncology (OSHO) (2008) Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. *Br J Haematol*. 143, 191-200
160. Johnson, D.C., Corthals, S., Ramos, C., Hoering, A., Cocks, K., Dickens, N.J., Haessler, J., Goldschmidt, H., Child, J.A., Bell, S.E., Jackson, G., Baris, D., Rajkumar, S.V., Davies, F.E., Durie, B.G., Crowley, J., Sonneveld, P., Van Ness, B., Morgan, G.J. (2008) Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. *Blood*. 112, 4924-4934
161. Hillengass, J., Ho, A.D., Goldschmidt, H., Waldherr, R., Moehler, T.M. (2008) Clinical evidence for immunomodulation induced by high-dose melphalan and autologous stem

cell transplantation as cause for complete clinical remission of multiple myeloma-associated cryoglobulin-vasculitis. *Int J Hematol.* 88, 454-456

162. Jourdan, M., Reme, T., Goldschmidt, H., Fiol, G., Pantesco, V., De Vos, J., Rossi, J.F., Hose, D., Klein, B. (2009) Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells. *Br J Haematol.* 145, 45-58
163. Richardson, P.G., Sonneveld, P., Schuster, M.W., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., Bladé, J., Boccadoro, M., Cavenagh, J.D., Boral, A.L., Esseltine, D.L., Wen, P.Y., Amato, A.A., Anderson, K.C., San Miguel, J. (2009) Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. *Br J Haematol.* 144, 895-903
164. Hose, D., Reme, T., Meissner, T., Moreaux, J., Seckinger, A., Lewis, J., Benes, V., Benner, A., Hundemer, M., Hielscher, T., Shaughnessy, J.D. Jr, Barlogie, B., Neben, K., Kramer, A., Hillengass, J., Bertsch, U., Jauch, A., De Vos, J., Rossi, J.F., Moehler, T., Blake, J., Zimmermann, J., Klein, B., Goldschmidt, H. (2009) Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. *Blood.* 113, 4331-4340
165. Sprynski, A.C., Hose, D., Caillot, L., Reme, T., Shaughnessy, J.D. Jr, Barlogie, B., Seckinger, A., Moreaux, J., Hundemer, M., Jourdan, M., Meissner, T., Jauch, A., Mahtouk, K., Kassambara, A., Bertsch, U., Rossi, J.F., Goldschmidt, H., Klein, B. (2009) The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. *Blood.* 113, 4614-4626
166. Hose, D., Moreaux, J., Meissner, T., Seckinger, A., Goldschmidt, H., Benner, A., Mahtouk, K., Hillengass, J., Reme, T., De Vos, J., Hundemer, M., Condomines, M., Bertsch, U., Rossi, J.F., Jauch, A., Klein, B., Moehler, T. (2009) Induction of angiogenesis by normal and malignant plasma cells. *Blood.* 114, 128-143
167. Bret, C., Hose, D., Reme, T., Sprynski, A.C., Mahtouk, K., Schved, J.F., Quittet, P., Rossi, J.F., Goldschmidt, H., Klein, B. (2009) Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells. *Br J Haematol.* 145, 350-368
168. Christensen, O., Lupu, A., Schmidt, S., Condomines, M., Belle, S., Meier, A., Hose, D., Neuber, B., Moos, M., Kleist, C., Terness, P., Ho, A.D., Goldschmidt, H., Klein, B., Hundemer, M., (2009) Melan-A/MART1 analogue peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24. *J Immunother.* 32, 613-621
169. Hillengass, J., Zechmann, C., Bäuerle, T., Wagner-Gund, B., Heiss, C., Benner, A., Ho, A., Neben, K., Hose, D., Kauczor, H.U., Goldschmidt, H., Delorme, S., Moehler, T. (2009) Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation. *Clin Cancer Res.* 15, 3118-3125
170. Bäuerle, T., Hillengass, J., Fechtner, K., Zechmann, C.M., Grenacher, L., Moehler, T.M., Heiss, C., Wagner-Gund, B., Neben, K., Kauczor, H.-U., Goldschmidt, H., Delorme, S. (2009) Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. *Radiology.* 252, 477-485
171. Fruehauf, S., Veldwijk, M.R., Seeger, T., Schubert, M., Laufs, S., Topaly, J., Wuchter, P., Dillmann, F., Eckstein, V., Wenz, F., Goldschmidt, H., Ho, A.D., Calandra, G. (2009) A combination of granulocyte colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. *Cytotherapy.* 11, 992-1001

172. Condomines, M., Hose, D., Rème, T., Requirand, G., Hundemer, M., Schoenhals, M., Goldschmidt, H., Klein, B. (2009) Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma. *J Immunol.* 183, 832-840
173. Seckinger, A., Meißner, T., Moreaux, T., Goldschmidt, H., Fuhler, G.M., Benner, A., Hundemer, M., Rème, T., Shaughnessy, J.D. Jr., Barlogie, B., Bertsch, U., Hillengass, J., Ho, A.D., Pantesco, V., Jauch, A., De Vos, J., Rossi, J.F., Moehler, T., Klein, B., Hose, D., [Geteilte Erstautorenschaft]. (2009) Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. *Oncogene.* 28, 3866-3879
174. Caers, J., Hose, D., Kuipers, I., Bos, T.J., Van Valckenborg, E., Menu, E., De Bruyne, E., Goldschmidt, H., Van Camp, B., Klein, B., Vanderkerken, K., [Geteilte Erstautorenschaft]. (2009 epub ahead of print; 2010 print) Thymosin Beta 4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma. *Haematologica.* 95, 163-167
175. Fruehauf, S., Ehninger, G., Hübel, K., Topaly, J., Goldschmidt, H., Ho, A.D., Müller, S., Moos, M., Badel, K., Calandra, G. (2009 epub ahead of print; 2010 print) Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. *Bone Marrow Transplant.* 45, 269-275
176. Hillengass, J., Neben, K., Goldschmidt, H. (2009 epub ahead of print; 2010 print) Current status and developments in diagnosis and therapy of multiple myeloma. *J Cancer Res Clin Oncol.* 136, 151-155
177. Kristen, A.V., Sack, F.-U., Schonland, S.O., Hegenbart, U., Helmke, B.M., Koch, A., Schnabel, P.A., Rocken, C., Hardt, S., Remppis, A., Goldschmidt, H., Karck, M., Ho, A.D., Katus, H.A., Dengler, T.J. (2009) Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis. *Eur J Heart Fail.* 11, 1014-1020
178. Rossi, J.F., Moreaux, J., Hose, D., Requirand, G., Rose, M., Rouillé, V., Nestorov, I., Mordenti, G., Goldschmidt, H., Ythier, A., Klein, B. (2009) Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study. *Br J Cancer.* 101, 1051-1058
179. Wuchter, P., Ran, D., Bruckner, T., Schmitt, T., Witzens-Harig, M., Neben, K., Goldschmidt, H., Ho, A.D. (2009 epub ahead of print; 2010 print) Poor mobilization of hematopoietic stem cells – definitions, incidence, risk factors and impact on outcome of autologous transplantation. *Biol Blood Marrow Transplant.* 16, 490-499
180. Rutsch, S., Neppalli, V.T., Shin, D.-M., DuBois, W., Morse, H.C., Goldschmidt, H., Janz, S. (2009 epub ahead of print; 2010 print) IL-6 and MYC collaborate in plasma cell tumor formation in mice. *Blood.* 115, 1746-1754
181. Hillengass, J., Fechtner, K., Weber, M.-A., Bäuerle, T., Ayyaz, S., Heiss, C., Hielscher, T., Moehler, T., Egerer, G., Neben, K., Ho, A., Kauczor, U., Delorme, S., Goldschmidt, H. (2010) Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. *J Clin Oncol.* 28, 1606-1610
182. Weinhold, N., Moreaux, J., Raab, M.S., Hose, D., Hielscher, T., Benner, A., Meißner, T., Ehrbrecht, E., Brough, M., Jauch, A., Goldschmidt, H., Klein, B., Moos, M. (2010) NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is

not delocalized to the cytoplasm. *Genes Chromosomes Cancer*. 49, 333-341

183. Ludwig, H., Beksac, M., Bladé, J., Boccadoro, M., Cavenagh, J., Cavo, M., Dimopoulos, M., Drach, J., Einsele, H., Facon, T., Goldschmidt, H., Harousseau, J.L., Hess, U., Ketterer, N., Kropff, M., Mendeleeva, L., Morgan, G., Palumbo, A., Plesner, T., San Miguel, J., Shpilberg, O., Sondergeld, P., Sonneveld, P., Zweegman, S. (2010) Current multiple myeloma treatment strategies with novel agents: a European perspective. *Oncologist*. 15, 6-25
184. Willhauck-Fleckenstein, M., Moehler, T.M., Merling, A., Pusunc, S., Goldschmidt, H., Schwartz-Albiez, R. (2010) Transcriptional regulation of the vascular endothelial glycome by angiogenic and inflammatory signalling. *Angiogenesis*. 13, 25-42
185. Neben, K., Jauch, A., Bertsch, U., Heiss, C., Hielscher, T., Seckinger, A., Mors, T., Müller, N.Z., Hillengass, J., Raab, M.S., Ho, A.D., Hose, D., Goldschmidt, H. (2010) Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. *Haematologica*. 95, 1150-1157
186. Dietrich, S., Schönland, S., Benner, A., Bochtler, T., Kristen, A.V., Beimler, J., Hund, E., Zorn, M., Goldschmidt, H., Ho, A.D., Hegenbart, U. (2010) Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. *Blood*. 116, 522-528
187. Mahtouk, K., Moreaux, J., Hose, D., Reme, T., Meissner, T., Jourdan, M., Rossi, J.F., Pals, S.T., Goldschmidt, H., Klein, B. (2010) Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays. *BMC Cancer*. 10, 198
188. Schmitt, S., Bertsch, U., Goldschmidt, H. (2010) Experiences with bortezomib in multiple myeloma – from Phase II studies to daily practice. *Int J Clin Pharmacol Ther*. 48, 496-496
189. Dimopoulos, M., Alegre, A., Stadtmauer, E.A., Goldschmidt, H., Zonder, J.A., de Castro, C.M., Masliak, Z., Reece, D., Olesnyckyj, M., Yu, Z., Weber, D.M. (2010) The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. *Cancer*. 116, 3807-3814
190. Moehler, T.M., Feneberg, R., Ho, A.D., Golenkov, A.K., Ludwig, H., Kropff, M., Khuageva, N.K., Hajda, J., von Broen, I., Goldschmidt, H. (2010) Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma. *Anticancer Drugs*. 21, 708-715
191. Broyl, A., Hose, D., Lokhorst, H., de Knegt, Y., Peeters, J., Jauch, A., Bertsch, U., Buijs, A., Stevens-Kroef, M., Beverloo, B., Vellenga, E., Zweegman, S., Kersten, M.-J., van der Holt, B., el Jairari, L., Mulligan, G., Goldschmidt, H., van Duin, M., Sonneveld, P. (2010) Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. *Blood*. 116, 2543-2553
192. Sprynski, A.C., Hose, D., Kassambara, A., Vincent, L., Jourdan, M., Rossi, J.F., Goldschmidt, H., Klein, B. (2010) Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation. *Leukemia*. 24, 1940-1950
193. Fechtner, K., Hillengass, J., Delorme, S., Heiss, C., Neben, K., Goldschmidt, H., Kauczor, H.-U., Weber, M.-A. (2010) Staging monoclonal plasma cell disease – Comparison of the Durie/Salmon and the Durie/Salmon PLUS staging system. *Radiology*. 257, 195-204

194. Moreaux, J., Hose, D., Bonnetfond, A., Reme, T., Robert, N., Goldschmidt, H., Klein, B. (2010) MYEOV is a prognostic factor in Multiple Myeloma. *Exp Hematol.* 38, 1189-1198
195. Klein, U., Neben, K., Hielscher, T., Heiß, C., Ho, A.D., Goldschmidt, H. (2010) Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. *Ann Hematol.* 2010 Sep 21. [Epub ahead of print]
196. Van de Donk, N.W., Lokhorst, H.M., Dimopoulos, M., Cavo, M., Morgan, G., Einsele, H., Kropff, M., Schey, S., Avet-Loiseau, H., Ludwig H., Goldschmidt, H., Sonneveld, P., Johnsen, H.E., Bladé, J., San-Miguel, J.F., Palumbo, A. (2010) Treatment of relapsed and refractory multiple myeloma in the era of novel agents. *Cancer Treat Rev.* 2010 Sep 20 [Epub ahead of print]
197. Broyl, A., Corthals, S.L., Jongen, J.L., van der Holt, B., Kuiper, R., de Knecht, Y., van Duin, M., El Jarari, L., Bertsch, U., Lokhorst, H.M., Durie, B.G., Goldschmidt, H., Sonneveld, P. (2010) Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. *Lancet Oncol.* 11, 1057-1065
198. Hose, D., Rème, T., Hielscher, T., Moreaux, J., Meissner, T., Seckinger, A., Benner, A., Shaughnessy, J.D. Jr, Barlogie, B., Zhou, Y., Hillengass, J., Bertsch, U., Neben, K., Moehler, T., Rossi, J.F., Jauch, A., Klein, B., Goldschmidt, H. (2010 epub ahead of print; 2011 print) Proliferation is a central independent prognostic factor and target for personalized and risk adapted treatment in multiple myeloma. *Haematologica.* 96, 87-95
199. Morris, C., Drake, M., Apperley, J., Iacobelli, S., van Biezen, A., Bjorkstrand, B., Goldschmidt, H., Jouet, J.P., Harousseau, J.L., Morgan, G., De Witte, T., Neiderwieser, D., Gahrton, G. (2010) Efficacy and outcome of autologous transplantation in rare myelomas. *Haematologica.* 95, 2126-2133
200. Moreaux, J., Hose, D., Kassambara, A., Reme, T., Moine, P., Requirand, G., Goldschmidt, H., Klein, B. (2010 epub ahead of print; 2011 print) Osteoclast-gene expression profiling reveals osteoclast-derived CCR2-chemokines promoting myeloma cell migration. *Blood.* 117, 1280-1290
201. Klein, U., Jauch, A., Hielscher, T., Hillengass, J., Raab, M.S., Seckinger, A., Hose, D., Ho, A.D., Goldschmidt, H., Neben, K. (2010 epub ahead of print; 2011 print) Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. *Cancer.* 2010 Dec 4 [Epub ahead of print]
202. Moreaux, J., Klein, B., Bataille, R., Descamps, G., Maiga, S, Hose, D., Goldschmidt, H., Jauch, A., Reme, T., Jourdan, M., Amiot, M., Pellat-Deceunynck, C. (2010 epub ahead of print; 2011 print) A high-risk signature for patients with multiple myeloma established from human myeloma cell lines molecular classification. *Haematologica.* 2010 Dec 29 [Epub ahead of print]
203. Johnson, D.C., Corthals, S.L., Walker, B.A., Ross, F.M., Gregory, W.M., Dickens, N.J., Lokhorst, H.M., Goldschmidt, H., Davies, F.E., Durie, B.G., Van Ness, B., Child, J.A., Sonneveld, P., Morgan, G.J. (2011) Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. *J Clin Oncol.* 2011 Jan 18. [Epub ahead of print]
204. Dimopoulos, M., Kyle, R., Femand, J.P., Rajkumar, S.V., San Miguel, J., Chanan-Khan, A., Ludwig, H., Joshua, D., Mehta, J., Gertz, M., Avet-Loiseau, H., Beksaç, M., Anderson, K.C., Moreau, P., Singhal, S., Goldschmidt, H., Boccadoro, M., Kumar, S.,

Giralt, S., Munshi, N.C., Jagannath, S. (2011) Guidelines for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011 Feb. 3 [Epub ahead of print]

### Arbeiten in anderen Journalen

1. Goldschmidt, H., Stobbe, H. (1986) Zur Klinik der autoimmunhämolytischen Anämien. Z Gesamte Innere Med. 41, 29-33
2. Goldschmidt, H., Stobbe, H. (1986) Folgen des Milzverlustes. Z ärztl Fortbild. 80, 607-609
3. Wächter, M., Goldschmidt, H., Blau, W., Elstner, E. (1986) Der Einfluss von Cytosin Arabinosid (ARA-C) auf granulozytär-monozytär determinierte Stammzellen (CFU-GM) und myeloische Blasten (CFU-L) in vitro. Folia Haematol. (Leipzig) 115, 927-934
4. Goldschmidt, H., Ihle, R., Stobbe, H. (1987) Indikationen zur Splenektomie aus internistisch-hämatologischer Sicht. Z ärztl Fortbild. 81, 1183-1187
5. Goldschmidt, H., Fenske, K. (1987) Hinweise zur Knochenmarkgewinnung für die hämatologische Diagnostik. Heilberufe. 39, 141-143
6. Goldschmidt, H., Elstner, E., Wulsche, H., Wächter, M., Ihle, R. (1987) Bestimmung der S-Phasen-fraktion myeloisch-determinierter Stammzellen (CFU-GM) mit der Cytosin Arabinosid-Suizid-Technik bei Patienten mit akuter myeloischer Leukämie in Vollremission nach Polychemotherapie. Arch Geschwulstforsch. 57, 385-392
7. Romberg, B., Blau, I.W., Goldschmidt, H., Ihle, H., Ihle, R. (1988) Der Stellenwert der Behandlung der akuten myeloischen Leukämie nach dem TAD-Protokoll – Eine retrospektive Studie. Klin Med. 43, 1843-1846
8. Elstner, E., Goldschmidt, H., Wächter, M., Blau, I.W., Grunze, S. (1988) Stammzellen der Blutbildung und Knochenmarkstroma. Heilberufe. 41, 99-100
9. Goldschmidt, H., Pönisch, W. (1989) Knochenmarktransplantation. Heilberufe 42, 57-59
10. Goldschmidt, H., Klaassen, U., Bokemeyer, C. (1992) Wilsede Schule für Onkologie und Hämatologie. Onkologie. 15, 403-404
11. Goldschmidt, H., Richter, T., Briedigkeit, H., Schultze, W., Ihle, R. (1992) Komplikationen zentralvenöser Katheter bei Patienten mit hämatologischen Erkrankungen. Z ärztl Fortbild. 86, 37-42
12. Haas, R., Hohaus, S., Ehrhardt, R., Goldschmidt, H., Hunstein, W. (1993) Autologous blood progenitor cell transplantation in relapsed Hodgkin's disease – the role of haematopoietic growth factors. Bone Marrow Transplant. 11, Suppl. 2, 30-35
13. Hahn, U., Reichardt, P., Haas, R., Goldschmidt, H. (1993) Subcutan getunnelte Katheter als permanenter zentralvenöser Zugang bei Intensivpatienten in der Hämatologie – Erfahrungen mit dem Cuff-Cath(R). Intensivmedizin und Notfallmedizin. 534-538
14. Goldschmidt, H. (1994) Grundlagen des Eisenstoffwechsels. Dtsch med Wschr. 119, 1278-1288

15. Goldschmidt, H. (1994) Eisenmangelanämie. Dtsch. med. Wschr. 119, 1403-1404
16. Hegenbart, U., Goldschmidt, H. (1994) Paroxysmale nächtliche Hämoglobinurie – Abgrenzung zu anderen erworbenen hämolytischen Anämien und Sicherung der Diagnose. Z ärztl Fortbild. 88, 39-42
17. Hegenbart, U., Salwender, H.-J., Goldschmidt, H. (1995) Fulminante Sepsis bei einem Patienten mit Plasmozytom und funktioneller Aplasie bei systemischer Amyloidose. Onkologie Service aktuell. 1, Heft 4, 13-14
18. Goldschmidt, H., Hegenbart, U., Haas, R., Hunstein, W. (1995) Hematopoietic blood progenitor cell transplantation in multiple myeloma. Onkologie. 18, 518-524
19. Goldschmidt, H., Haas, R. (1995) High-dose chemotherapy with blood stem-cell transplantation in the treatment of solid tumors and hematological malignancies. J Cancer Res Clin Oncol. 121, 383-384
20. Moos, M., Schulz, R., Cremer, F., Sucker, C., Schmohl, D., Döhner, H., Goldschmidt, H., Haas, R., Hunstein W. (1995) Detection of minimal residual disease by polymerase chain reaction (PCR) in B-cell malignancies. Stem Cells. 13, Suppl. 3, 42-51
21. Goldschmidt, H. (1996) „Hochmalignes T-Zell-Lymphom“ – Manifestation einer CML-Blastenkrise. Onkologie Service aktuell. 2, Heft 2, 12-13
22. Hegenbart, U., Egerer, G., Goldschmidt, H. (1996) Ausgeprägte Leukozytose und Hyperkalzämie bei einem 29jährigen Patienten. Der Onkologe. 2, 296-299
23. Goldschmidt, H., Haas, R., Hegenbart, U., Wallmeier, M., Egerer, G., Moos, M., Engenhardt, R., Wannenmacher, M., Hunstein, W. (1996) Hochdosistherapie beim Multiplen Myelom. Der Onkologe. 2, Suppl. 1, 6-12
24. Goldschmidt, H., Wallmeier, M., Hegenbart, U., Haas, R. (1997) Maligne Lymphome: Pathologie, Diagnostik, Therapie. Der Radiologe. 37, 1-9
25. Moos, M., Schulz, R., Cremer, F., Kiel, K., Schmohl, D., Döhner, H., Goldschmidt, H., Haas, R. (1998) Nachweis von minimaler Resterkrankung bei malignen B-Zell-Erkrankungen mit Hilfe der Polymerase-Ketten-Reaktion. J Lab Med. 22, 15-21
26. Hohmann, M., Sabo, D., Parsch, D., Rickert, M., Goldschmidt, H., Brocai, D., Ewerbeck, V. (1999) Multiples Myelom: Orthopädische Therapie am Stütz- und Bewegungsapparat. Der Onkologe. 5, 321-326
27. Goldschmidt, H., Egerer, G., Ho, A.D. (2000) Autologous and allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant. 25, 25-26
28. Cremer, F.W., Goldschmidt, H. (2000) Multiple Myeloma – current concepts for an interdisciplinary management. J Cancer Res Clin Oncol. 126, 119-123
29. Goldschmidt, H., Lannert, H., Bommer, J., Ho, A.D. (2000) Multiple myeloma and renal failure. Nephrol Dial Transplant. 15, 301-304
30. Moehler, T.M., Hawighorst, H., Neben, K., Egerer, G., Benner, A., Hillengass, J., Max, R., Ho, A.D., Goldschmidt, H., van Kaick, G. (2000) Funktionelle Magnetresonanztomographie in Diagnostik und Therapiemonitoring beim Multiplen Myelom. Der Radiologe. 40, 723-730
31. Goldschmidt, H., Lannert, H., Bommer, J., Ho, A.D. (2001) Renal failure in multiple

- myeloma "the myeloma kidney": state of the art. *Saudi J Kidney Diseases and Transplant.* 2, 145-150
32. Moehler, T., Neben, K., Ho, A.D., Goldschmidt, H. (2001) Angiogenesis in haematologic malignancies. *Ann Haematol.* 80, 695-705
  33. Djulbegovic, B., Wheatley, K., Ross, J., Clark, O., Bos, G., Goldschmidt, H., Cremer, F., Alsina, M., Glasmacher, A. (2001) Bisphosphonates in multiple myeloma. *Cochrane Database Syst Rev.* 2001; (4): CD003188. Review
  34. Görner, M., Höpfner, S., Goldschmidt, H., Ho, A.D. (2002) Allogeneic immunotherapy for relapsed multiple myeloma: Role of matched unrelated donors. *Chinese-German J Clin Oncol.* 1, 72-74
  35. Goldschmidt, H., Cremer, F., Moehler, T., Egerer, G., Görner, M., Krämer, A., Ho, A.D. (2002) Therapy of multiple myeloma. *Chinese-German J Clin. Oncol* 1, 141-144
  36. Egerer, G., Harter, C., Karthaus, M., Ho, A.D., Goldschmidt, H. (2003) Use of erythropoietin in multiple myeloma. *Onkologie* 26, 80-84
  37. Goldschmidt, H., Cremer, F.W., Möhler, T., Ho, A.D. (2003) Multiples Myelom – Diagnostik und Therapie. *Der Onkologe.* 9, 1152-1168
  38. Goldschmidt, H., Egerer, G., Fruehauf, S., Ho, A.D. (2003) Die Stammzelle in der Hämatologie und Onkologie. *Med Klin.* 98, Suppl. II, 11-14
  39. Goldschmidt, H., Sonneveld, P., Cremer, F.W., van der Holt, B., Westveer, P., Breitkreutz, I., Benner, A., Glasmacher, A., Schmidt-Wolf, I., Martin, H., Hoelzer, D., Ho, A.D., Lokhorst, H.M. (2003) The joint HOVON-50/GMMG-HD-3 randomized trial on the effect of thalidomide as a part of high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. *Ann Haematol.* 82, 654-659
  40. Goldschmidt, H., Cremer, F., Möhler, T., Ho, A. (2003) Multiples Myelom, Diagnostik und Therapie. *Der Internist.* 44, 599-618
  41. Sucker, C., Krämer, A., Moos, M., Goldschmidt, H. (2004) Concomitant chronic lymphocytic leukemia and multiple myeloma: proof of common clonal origin. *Chinese-German J Clin Oncol.* 3, 81-84
  42. Moehler, T.M., Hillengass, J., Goldschmidt, H., Ho, A.D. (2004) Antiangiogenic therapy in hematologic malignancies. *Curr Pharm Des.* 10, 1221-1234
  43. Morath, C., Mueller, M., Goldschmidt, H., Schwenger, V., Opelz, G., Zeier, M. (2004) Malignancy in Renal Transplantation. *J Am Soc Nephrol.* 15, 1582-1588
  44. Goldschmidt, H., Cremer, F., Möhler, T. (2004) Multiples Myelom, Diagnose und Klinik, *Der Onkologe.* 8, 809-819
  45. Hose, D., Cremer, F., Goldschmidt, H. (2005), Multiples Myelom: Diagnostik, Klinik und Therapie. *Spektrum der Nephrologie.* 18, 14-23
  46. Knaebel, H.P., Marten, A., Schmidt, J., Hoffmann, K., Seiler, C., Lindel, K., Schmitz-Winnenthal, H., Fritz, S., Herrmann, T., Goldschmidt, H., Krempien, R., Mansmann, U., Debus, J., Diehl, V., Buchler, M.W. (2005) Phase III trial of postoperative Cisplatin, Interferon Alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma – CapRI: study protocol [ISRCTN62866759], *BMC Cancer.* 5, 37

47. Goldschmidt, H. Moehler, T. (2005) Rezidivtherapie des Multiplen Myeloms. *Onkologisch.* 3, 6-7
48. Mazitschek, U., Cremer, F.W., Knauf, W., Goldschmidt, H. (2005) German-Speaking Myeloma Multicenter Group (GMMG). *Onkologisch.* 3, 11-12
49. Cremer, F., Sonneveld, P., Lokhorst, H., Hose D., Mazitschek, U., Goldschmidt, H. (2005) Proteasome inhibitors in multiple myeloma and other malignant diseases. *Europ J Hosp Pract.* 11, 44-45
50. Kristen, A.V., Meyer, F.J., Perz, J.B., Schönland, S.O., Hundemer, M., Hegenbart U., Singer R., Schnabel, P.A., Sack, F.U., Goldschmidt, H., Katus, H.A., Dengler, T. J. (2005) Risk stratification in cardiac amyloidosis: Novel approaches. *Transplantation.* 80, 151-155.
51. Singer, R., Mehrabi, A., Schemmer, P., Kashfi, A., Hegenbart, U., Goldschmidt, H., Schönland, S., Kristen, A., Dengler, T., Müller-Schilling, M., Sauer, P., Dogan, A., Hund, E., Helmke, B., Schnabel, P., Altland, K., Linke, R., Friess, H., Schmidt, J., Büchler, M. W., Kraus, T. W. (2005) Indications for liver transplantation in patients with amyloidosis: A single-center experience with 11 cases. *Transplantation.* 80, 156-159
52. Schönland, S.O., Perz, J.B., Hundemer, M., Hegenbart, U., Kristen, A.V., Hund, E., Dengler T.J., Beimler, J., Zeier, M., Singer, R., Linke R. P., Ho, A.D., Goldschmidt, H. (2005) Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis. *Transplantation.* 80, 160-163
53. Schönland, S., Hegenbart, U., Singer, R., Goldschmidt, H. (2005) Diagnostisches Vorgehen bei Verdacht auf eine Plasmazelldyskrasie. *Der Internist.* 9, 1057-1058
54. Moehler, T.M., Hillengass, J., Glasmacher, A., Goldschmidt, H. (2006) Thalidomide in multiple myeloma. *Curr Pharm Biotechnol.* 7, 431-440
55. Jochims, C., Mazitschek, U., Jäger, D., Goldschmidt, H. (2006) Zielgerichtete Therapie bei soliden Tumoren: Fortschritte und Enttäuschungen. *Der Internist.* 47, 633-41.
56. De Vos, J., Hose, D., Rème, T., Tarte, K., Moreaux, J., Mahtouk, K., Jourdan, M., Goldschmidt, H., Rossi, J.-F., Cremer, F.W., Klein, B. (2006) Microarray-based understanding of normal and malignant plasma cells. *Immunol Rev.* 210, 86-104
57. Perz, J.B., Kristen, A.V., Rahemtulla, A., Parameshwar, J., Sack, F.U., Apperley, J.F., Goldschmidt, H., Katus, H.A., Dengler, T.J. (2006) Long-term survival in a patient with AL amyloidosis after cardiac transplantation followed by autologous stem cell transplantation. *Clin Res Cardiol.* 95, 671-674
58. Goldschmidt, H. (2006) Multiples Myelom, Epidemiologie, Ätiologie und Pathogenese, Klinische Symptomatik und diagnostisches Konzept, Initiale Behandlungsoptionen und Rezidivtherapie. *Der Orthopäde.* 2, 1-8
59. Hose, D., Goldschmidt, H. (2007) Multiples Myelom: konventionelle Diagnostik. *Krebsmedizin.* 16, 6-12
60. Hose, D., Bertsch, U., Goldschmidt, H. (2007) Multiples Myelom: innovative Diagnostik. *Krebsmedizin.* 16, 14-18
61. Hillengaß, J., Hansmann, J., Goldschmidt, H., Mohler, T.M. (2007) Bildgebende Verfahren beim multiplen Myelom. *Krebsmedizin.* 16, 19-24

62. Goldschmidt, H., Bertsch, U., Moehler, T. (2007) Primärtherapie des multiplen Myeloms. Krebsmedizin. 16, 25-28
63. Klein, U., Moehler, T., Goldschmidt, H. (2007) Rezidivtherapie des multiplen Myeloms. Krebsmedizin. 16, 29-33
64. Kropff, M., Knauf, W., Goldschmidt, H., Angermund R. (2007) Thrombozytopenie bei der Behandlung des Multiplen Myeloms mit Bortezomib. Arzneimitteltherapie. 2, 51-53
65. Goldschmidt, H. (2007) Bortezomib in der Therapie des multiplen Myeloms. Tumordiagnostik & Therapie. Thieme Drug report. 3, 1-18
66. Goldschmidt, H., Klein, U., Musch, A. (2008) Lenalidomid. Therapie des multiplen Myeloms. Arzneimitteltherapie. 2, 42-48
67. Goldschmidt, H., Neben, K. (2008) Neue Substanzen in der Therapie des multiplen Myeloms. Onkologisch. 2, 4-5
68. Knop, S. und Einsele, H.; Bertsch und U., Goldschmidt, H. (2008) Multiples Myelom – aktuelle Therapiekonzepte. Onkologisch. 2, 10-12
69. Hillengass, J., Weber, M.-A., Goldschmidt, H. (2008) Nachweis eines systemischen multiplen Myeloms mittels neuer bildgebender Verfahren bei einer Patientin mit dem Verdacht auf ein solitäres Plasmozytom. Onkopipeline. 1, 17-20
70. Goldschmidt, H. (2008) Historie des multiplen Myeloms. Onkopipeline. 1, 21-22
71. Goldschmidt, H. (2008) Therapie des multiplen Myeloms. Onkopipeline. 1, 30-34
72. Goldschmidt, H. (2008) Diagnostik des multiplen Myeloms. Tumordiagnostik & Therapie. 29, 178-181
73. Goldschmidt, H. (2008) Therapie des multiplen Myeloms. Tumordiagnostik & Therapie. 29, 182-185
74. Kropff, M., Knauf, W., Kornacker, M., Goldschmidt, H. (2008) Prophylaxe der Varicella-Zoster-Virus-Reaktivierung bei der Behandlung des multiplen Myeloms mit Bortezomib. Arzneimitteltherapie. 10, 357-361
75. Hillengass, J., Neben, K., Goldschmidt, H. (2008) Erfahrungen mit einer interdisziplinären Konferenz. Klinikarzt. 37, 510
76. Klein, U., Goldschmidt, H. (2008) Schwieriger Balanceakt mit immunmodulatorischen Substanzen. Im Focus Onkologie. 11, 77-80
77. Goldschmidt, H., Salwender, H.-J., Knauf, W. (2009) Multiples Myelom: Von Diagnostik über Hochdosistherapie bis zu neuen Substanzen. best practice onkologie. 1, 4-13
78. Goldschmidt, H. (2009) Autologe Stammzelltransplantation beim multiplen Myelom – pro. Dtsch Med Wochenschr. 134, 1942
79. Schmitt, S., Ho, A.D., Goldschmidt, H. (2010) The Oral Histone Deacetylase Inhibitor LBH589 Is a Potential and Promising Therapeutic Agent in Multiple Myeloma after at Least Two Lines of Chemotherapy Including Bortezomib or Lenalidomide. Onkologie. 33, 183-186

80. Hillengaß, J., Goldschmidt, H. (2010) Multiples Myelom: Epidemiologie und Stadieneinteilung. Der Onkologe. 3, 225-231
81. Hillengaß, J., Goldschmidt, H. (2010) Prognostische Bedeutung der Ganzkörper-MRT bei Patienten mit asymptomatischem Multiplen Myelom. DZKF. 5/6, 41-42
82. Goldschmidt, H. (2010) Therapie des jüngeren Patienten mit Multiplem Myelom. Ärztliche Praxis Onkologie. 3, 8-10
83. Raab, M.-S., Goldschmidt, H. (2010) Aktuelle Entwicklungen in der Therapie des Multiplen Myeloms. Arzneimitteltherapie. 28, 305-316
84. Goldschmidt, H. (2010) Aktuelle Therapieoptionen des Multiplen Myeloms. Forum Sanitas. 4. Ausgabe 2010, 36-38
85. Knauf, W., Kellermann, L., Poenisch, W., Einsele, H., Straka, C., Frohn, C., Goldschmidt, H. (2010) How to treat multiple myeloma – a representative multicentre treatment survey. Onkologie. 33, 604-610

### **Buchbeiträge**

1. Elstner, E., Goldschmidt, H., Wächter, M., Ihle, R. Sensitivity of stromal elements from human bone marrow cells to cytosine arabinoside in vitro, in: Neth R., Gallo R.C., Greaves M.F. and Kabisch H. (Eds.): Modern Trends in Human Leukemia VII, Springer, Berlin, Heidelberg, New York, Tokyo 1987, 177-180
2. Ihle, R., Blau, W., Elstner, E., Goldschmidt, H., Wächter, M. Zum Einfluß von Antimetaboliten auf die normale und leukämisch transformierte Hämatopoese in vitro, in: Lutz, D., Heinz, R., Nowotny, H., Stacher, A. (Eds.): Leukämien und Lymphome, Urban und Schwarzenberg, München, Wien, Baltimore, 1988, 229-233
3. Goldschmidt, H., Debatin, K.M., Flentje, M., v. Kalle, A.K., Möller, P., Queißer, W., Worst, P. Morbus Hodgkin – Empfehlungen für eine standardisierte Diagnostik, Therapie und Nachsorge. Schriftenreihe des Tumorzentrums Heidelberg/Mannheim 1993
4. Goldschmidt, H., Hahn, U., Bentz, M., Kappe, R., Möller, P., Haas, R., Hunstein, W. Gastric zygomycosis following autologous bone marrow transplantation, in: Einhorn, J., Nord, C.E., Norry, S.R. (Eds.): Recent Advances in Chemotherapy: Proceedings of the 18<sup>th</sup> International Congress of Chemotherapy, Stockholm 1993, 703-704
5. Goldschmidt, H., Hahn, U., Jahns, T., Strohmaier, A., Rinck, M., Jansen, M., Hunstein, W. Infectious complications associated with central venous catheters in oncological patients, in: Einhorn, J., Nord, C.E., Norry, S.R. (Eds.): Recent Advances in Chemotherapy: Proceedings of the 18<sup>th</sup> International Congress of Chemotherapy, Stockholm 1993, 91-92
6. Haas, R., Ehrhardt, R., Hohaus, R., Goldschmidt, H., Hunstein, W. Mobilization regimens for peripheral blood stem cells – the role of G-CSF, GM-CSF and IL-3. Recent Advances in Hematopoietic Stem Cell Transplantation – Clinical Progress, New Technologies and Gene Therapy, San Diego, March 1993, 179-189
7. Haas, R., Hohaus, S., Ehrhardt, R., Goldschmidt, H., Hunstein, W. Mobilization of Blood Stem Cells with Recombinant Human (rh) G-CSF in Patients with Hematological Malignancies and Solid Tumors, in: Wunder, E.W. and Henon, P.R. (Eds.): Peripheral

- Blood Stem Cell Autografts, Springer, Berlin, Heidelberg, New York, Tokyo 1993, 155-167
8. Hahn, U., Deboben, A., Baldauf, G., Goldschmidt, H., Haas, R., Hunstein, W. Liposomal amphotericin B (Ambisome) in patients with severe neutropenia and antibiotic resistant fever, in: Büchner et al. (Eds.): Acute Leukemias IV. Prognostic Factors, Springer, Berlin Heidelberg, New York, Tokyo 1993, 614-661
  9. Hahn, U., Reichardt, P., Haas, R., Goldschmidt, H., Hunstein, W. Cuff-cath - a novel indwelling intravenous catheter used for hematological care unit patients, in: Einhorn, J., Nord, C.E., Norry, S.R. (Eds.): Recent Advances in Chemotherapy: Proceedings of the 18<sup>th</sup> International Congress of Chemotherapy, Stockholm 1993, 740-741
  10. Richter, E., Barz, D., Blauärmel, O., Staffa, G., Manger, T., Goldschmidt, H., Schultze, W., Matthes, H. Leukocyte depletion of red cell and platelet concentrates: clinical importance to patients awaiting organ transplantation, in: Segiguchi, S. (Ed.): Clinical Application of Leukocyte Depletion, Blackwell Scientific Publications, Oxford, London, Edinburgh, Boston, Melbourne, Paris, Berlin, Vienna 1993, 183-191
  11. Goldschmidt, H., Hohaus, S., Pförsich, M., Moos, M., Haas, R., Hunstein, W. Mobilization of peripheral blood stem cells with rhG-CSF during steady-state hemopoiesis, in: Freund, M., Link, H., Welte, K. (Eds.): Cytokines in Hematology, Oncology and Immunology, Springer, Berlin, Heidelberg, New York, Tokyo 1994, 153-159
  12. Schmid, H., Haas, R., Krämer, A., Goldschmidt, H., Kaufmann, M., Bastert, G., Hunstein, W. Dosisintensivierte Chemotherapie mit Stammzellsupport in der gynäkologischen Onkologie, in: Bastert et al. (Eds): Immuntherapie in der gynäkologischen Praxis, Springer, Berlin, Heidelberg, New York 1994, 93-105
  13. Haas, R., Goldschmidt, H., Moos, M., Frühauf, S., Möhle, R., Karcher, A., Witt, B., Flentje, M., Wannemacher, M., Hunstein, W. High-dose therapy with peripheral blood stem cell support in patients with non-Hodgkin Lymphoma, in: Zeller, W.J., Eisenbrand, G., Hellmann, K. (Eds.): Reduction of Anticancer Drug Toxicity. Pharmacologic, Biologic, Immunologic and Gene Therapeutic Approaches. Contrib. Oncol., Karger, Basel 1995, 48, 72-79
  14. Haas, R., Moos, M., Goldschmidt, H., Möhle, R., Fischer, K., Flentje, M., Wannemacher, M., Witt, B., Hunstein, W. Peripheral blood progenitor cell (PBPC) support in low- and intermediate-grade non-Hodgkin's lymphoma (NHL), in: Dicke K.A., Keating, A. (Eds.): Autologous Marrow and Blood Transplantation. Proceedings of the Seventh International Symposium, Arlington, Texas 1995, 613-621
  15. Strauss, L.G., Dimitrakopoulou-Strauss, A., Goldschmidt, H., Lorenz, W.J., van Kaick, G. PET with FDG and SPECT with Tc-99m-Sestamibi for therapy management in patients with treated malignant lymphomas. Extended synopses of the symposium on tomography in nuclear medicine, present status and future prospects. International Atomic Energy Agency in co-operation with the World Health Organization, IAEA-SM-337/5 (1995)
  16. Dimitrakopoulou-Strauss, A., Strauss, L.G., Goldschmidt, H., Oberdorfer, F., Schilling, P., Abercorn, U., Kakavetsis, N., van Kaick, G. Biological characterization and multidrug resistance (MDR) in patients with recurrent lymphomas using positron emission tomography (PET) and single photon emission tomography (SPET), in: Proceedings of the European Conference on Research and Application of Positron in Oncology: Metabolic Imaging of Cancer, AMJ Paans et al. (Eds.), PET-Centrum AZG, Groningen 1996, 25-27
  17. Haas, R., Goldschmidt, H., Möhle, R., Frühauf, S., Hohaus, S., Witt, B., Mende, U.,

- Flentje, M., Wannemacher, M., Hunstein, W. High-dose therapy and autografting with mobilized peripheral blood progenitor cells in patients with malignant lymphoma, in: Hiddemann et al. (Eds.): Acute leukemias V, Springer, Berlin, Heidelberg, New York, Tokyo 1996, 398-404
18. Strauss, L.G., Dimitrakopoulou-Strauss, A., Goldschmidt, H., Lorenz, W.J., van Kaick, G. PET with <sup>19</sup>FDG and SPECT with <sup>99m</sup>Tc-SESTAMIBI for therapymanagement in patients with treated malignant lymphoma, in: Tomography in nuclear medicine, International Atomic Energy Agency, Vienna 1996, 167-176
  19. Goldschmidt, H. Multimodale Therapie beim multiplen Myelom und bei malignen Lymphomen, in: Wannemacher, M., Lehnert, T. (Eds.): Multimodale Kombinations-therapien. Johann Ambrosius Barth, Heidelberg-Leipzig 1997, 11
  20. Goldschmidt, H., Hegenbart, U., Wallmeier, M., Hohaus, S., Engenhardt, R., Wannemacher, M., Haas, R. Peripheral blood progenitor cell transplantation in multiple myeloma (MM) following high-dose melphalan-based therapy, in: Haas, R., Sczakiel, G. (Eds.): Hematopoietic Stem Cell Transplantation and Gene Therapy, Recent Results in Cancer Research. Springer, Heidelberg, New York, Tokyo 1997, 27-36
  21. Goldschmidt, H., Hegenbart, U., Wallmeier, M., Moos, M., Haas, R., Wannemacher, M., Hunstein, W. High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma, in: Dicke, K.A., Keating, A. (Eds.): Autologous Marrow and Blood Transplantation. Proceedings of the Eighth International Symposium, Arlington, Texas 1997, 243-250
  22. Goldschmidt, H., Murea, S., Moos, M., Hohaus, S., Voso, M.T., Haas, R. High-dose therapy with peripheral blood stem cell (PBSC) transplantation in patients with follicular lymphomas. Proceedings of the 5<sup>th</sup> Meeting Cellular Haematology, Alicante 1997, 34-35
  23. Haas, R., Murea, S., Hohaus, S., Goldschmidt, H., Engenhardt, R., Wannemacher, M., Hunstein, W. Myeloablative high-dose therapy with peripheral blood stem cell transplantation in patients with low-grade non-Hodgkin's lymphoma, in: Dicke, K.A., Keating, A. (Eds.): Autologous Marrow and Blood Transplantation. Proceedings of the Eighth International Symposium, Arlington, Texas 1997, 167-176
  24. Haas, R., Murea, S., Hohaus, S., Moos, M., Goldschmidt, H., Wannemacher, M., Hunstein, W. Myeloablative Hochdosistherapie mit Blutstammzellentransplantation bei Patienten mit zentroblastisch-zentrozytischem Non-Hodgkin-Lymphom, in: Höffkes, H.-G., Uppenkamp, M. (Eds.): Maligne Lymphome, Springer, Heidelberg, New York, Tokio 1997, 138-145
  25. Moos, M., Hegenbart, U., Cremer, F., Kiel, K., Wallmeier, M., Hohaus, S., Haas, R., Goldschmidt, H. PBPC-Mobilization in multiple myeloma: High-dose chemotherapy plus G-CSF versus G-CSF in steady state, in: Dicke, K.A., Keating, A. (Eds.): Autologous Marrow and Blood Transplantation. Proceedings of the Eighth International Symposium, Arlington, Texas 1997, 553-560
  26. Murea, S., Hohaus, S., Fruehauf, S., Kronenwett, R., Goldschmidt, H., Haas, R. Mobilization of peripheral blood progenitor cells following G-CSF-supported cytotoxic chemotherapy for autologous transplantation, in: Dicke, K.A., Keating, A. (Eds.): Autologous Marrow and Blood Transplantation. Proceedings of the Eighth International Symposium, Arlington, Texas 1997, 403-414
  27. Goldschmidt, H., Stobbe, H. Hämatologie/Onkologie, in: Zetkin, M., Schaldach, H.: Lexikon der Medizin, Ullstein Mosby, Wiesbaden, 16. Aufl. 1998

28. Goldschmidt, H. Therapiebedingte onkologische Notfallsituationen: Notfälle durch Störungen der Blutbildung, Diagnostik, in: Drings, P. (Ed.): Onkologische Notfälle – Empfehlungen für eine standardisierte Diagnostik, Therapie und Nachsorge. Steinkopf, Darmstadt 1999, 86-99
29. Goldschmidt, H. Tumorbedingte onkologische Notfallsituationen: Notfälle durch Störungen der Blutbildung, Therapie, in: Drings, P. (Ed.): Onkologische Notfälle – Empfehlungen für eine standardisierte Diagnostik, Therapie und Nachsorge. Steinkopf, Darmstadt 1999, 143-146
30. Egerer, G., Hegenbart, U., Salwender, H.J., Goldschmidt, H., Ho, A.D. Treatment of chemotherapy-induced emesis, in: Karthaus, D. and Ganser, A. (eds.): Supportive care in cancer patients. Karger, Basel 2000, 171-183
31. Egerer, G., Karthaus, M., Goldschmidt, H., Ho, A.D. Antimicrobial therapy in neutropenic patients, in: Karthaus, D. and Ganser, A. (Eds.): Supportive care in cancer patients. Karger, Basel 2000, 20-25
32. Salwender, H.J., Egerer, G., Bach, A., Hahn, U., Goldschmidt, H., Ho, A.D. Central venous catheter-related complications, in: Karthaus, D. and Ganser, A. (Eds.): Supportive care in cancer patients, Karger, Basel 2000, 113-143
33. Stilgenbauer, F., Egerer, G., Karthaus, M., Goldschmidt, H., Ho, A.D. Recombinant human erythropoietin in the treatment of cancer, in: Karthaus, D. and Ganser, A. (Eds.): Supportive care in cancer patients, Karger, Basel 2000, 106-114
34. Goldschmidt, H., Martin, H., Serke, S., Schultze, W., Hegenbart, U., Glasmacher, A., Ko, Y., Hänel, A., Rudolph, C., Gerhartz, H., Hastka, J., Wilhelm, M., Gieseler, F., Bornhäuser, M., Ehninger, G., Hehlmann, R., Hoelzer, D., Huhn, D., Haas, R., Ho, A.D. Tandem autologous transplantation (TPX) for multiple myeloma (MM): results of a German multicenter study, in: Schultze, W. (Ed.): High-Dose Therapy and Transplantation of Haematopoietic Cells. Blackwell, Berlin, Vienna 2000, 15-20
35. Görner, M., Kordelas, L., Thalheimer, M., Luft, T., Ustaoglu, F., Pfeiffer, S., Moehler, T., Moos, M., Goldschmidt, H., Ho, A.D. Non-myeloablative allogeneic stem cell transplantation in relapsing multiple myeloma: low transplant-related morbidity and mortality, in: Schultze, W. (Ed.): High-Dose Therapy and Transplantation of Haematopoietic Cells. Blackwell, Berlin, Vienna 2002, 10-15
36. Moehler, T.M., Neben, K., Kasper, B., Kordelas, L., Egerer, G., Görner, M., Ho, A.D., Goldschmidt, H. Thalidomide plus CED chemotherapy as remission induction regimen for poor prognosis multiple myeloma before autologous or allogeneic hematopoietic stem cell transplantation, in: Schultze, W. (Ed.): High-Dose Therapy and Transplantation of Haematopoietic Cells, Blackwell, Berlin, Vienna 2002, 113-119
37. Goldschmidt, H., Peest, D. Multiples Myelom (Plasmozytom), in: Classen, M., Dierkesmann, R., Heimpel, H., Koch, K.-M., Meyer, J., Müller, O.-A., Specker, C., Theiss, W.: Empfehlungen der DGIM/BDI/DGHO „Rationelle Diagnostik und Therapie in der Inneren Medizin“, Urban & Fischer, München, Jena 2003, 11 B, 1-4
38. Ho, A.D., Goldschmidt, H. Früherkennung bei Hämoblastosen, in: Schadendorf, D., Queisser, W.: Krebsfrüherkennung. Schriftenreihe des Tumorzentrums Heidelberg/Mannheim, Steinkopff, Darmstadt 2003, 109-120
39. Glasmacher, A., Goldschmidt, H., Schmidt-Wolf, I. Interferon-alpha in der Therapie des Multiplen Myeloms, in: Die Interferone, Uni-Med Verlag AG, Bremen, London, Boston 2003, 48-58

40. Klein, U., Goldschmidt, H. Multiples Myelom, in: Pschyrembel: Therapiewörterbuch, Walter de Gruyter, 2005, 651-656
41. Delorme, S., Goldschmidt, H. Radiologische Diagnostik bei malignen Erkrankungen, in: Layer, B., van Kaick, G., Delorme, S. (Eds.): Radiologische Diagnostik in der Onkologie, Springer, Heidelberg, New York, Tokio 2006, 239-270
42. Goldschmidt, H. Multiples Myelom (Plasmozytom), in: Pfeifer, Preiß, Unger: Onkologie integrativ. Konventionelle und komplementäre Therapie, Urban und Fischer 2006, 705-713
43. Witzens-Harig, M., Goldschmidt, H. Hämatologie, in: Kurzlehrbuch Innere Medizin, Georg Thieme Verlag Stuttgart, New York 2007, 117-164
44. Goldschmidt, H. Multiples Myelom, in: NHL Diagnostik und Therapie, State of the Art 2007, Agileum, München 2007, 220-241
45. Moehler, T.M., Hillengass, J., Glasmacher, A., Goldschmidt, H. Thalidomide in Multiple Myeloma, in: Marmé, D., Fusenig, N. (Eds.): Tumor Angiogenesis: Basic mechanisms and cancer therapy. Springer 2008, 779-794
46. Goldschmidt, H. Stellenwert von G-CSF bei der Behandlung des Multiplen Myeloms (MM), in: Ehninger, G., Sölch, J.-P., Welte (Eds): Neue Trends zu G-CSF in der Onkologie, Springer Heidelberg 2008, 110-116
47. Goldschmidt, H. Multiples Myelom (MM, Plasmozytom), in: Preiß, J., Dornoff, W., Hagmann, F.-G., Schmieder, A.: Onkologie 2008/09. Interdisziplinäre Empfehlungen zur Therapie. 14. überarbeitete Neuauflage, W. Zuckschwerdt 2008, 70-73
48. Goldschmidt, H. Multiples Myelom, in: Hiddemann, W., Bartram, C. (Eds.): Die Onkologie. 2. aktualisierte Auflage, Springer, Heidelberg 2009, 1590-1607
49. Goldschmidt, H., Klein, U. Multiples Myelom, in: Pschyrembel: Therapie, 4. überarbeitete Auflage, Walter de Gruyter GmbH & Co. KG, Berlin 2009, 695-701
50. Goldschmidt, H. Wandel in der Therapie des Multiplen Myeloms, in: Ehninger, G., Freund, M., Overkamp, F. (Eds.): Colloquium Onkologie Band 7: Dresdner Symposium Hämatologie und Onkologie 2008. LUKON Verlagsgesellschaft 2009, 2-20
51. Goldschmidt, H. Multiples Myelom (MM, Plasmozytom), in: Preiß, J., Dornoff, W., Hagmann, F.-G., Schmieder, A.: Onkologie 2010/11. Interdisziplinäre Empfehlungen zur Therapie. 15. überarbeitete Neuauflage, W. Zuckschwerdt 2010, 60-64
52. Goldschmidt, H., Witzens-Harig, M. Hämatologie, in: Kurzlehrbuch Innere Medizin, überarbeitete Neuauflage, Georg Thieme Verlag Stuttgart, New York 2010, 101-139
53. Kortüm, M., Einsele, H., Naumann, R., Peest, D., Liebisch, P., Goldschmidt, H. (2010) Multiples Myelom. Leitlinie. Online publiziert auf der Seite der Deutschen Gesellschaft für Hämatologie und Onkologie (DGHO):  
<http://www.dgho.de/onkopedia/Multiples%20Myelom>
54. Kortüm, M., Einsele, H., Naumann, R., Peest, D., Liebisch, P., Goldschmidt, H. (2010) Monoklonale Gammopathie unklarer Signifikanz (MGUS). Leitlinie. Online publiziert auf der Seite der Deutschen Gesellschaft für Hämatologie und Onkologie (DGHO):  
<http://www.dgho.de/onkopedia/Monoklonale%20Gammopathie%20unklarer%20Signifikanz%20%28MGUS%29>

## **Buchveröffentlichungen**

1. Goldschmidt, H., Cremer F. Das Multiple Myelom (Plasmozytom) – Diagnose und Therapie. Uni-Med Verlag AG, Bremen, London, Boston 2002 (aktualisierte Neuauflage für 2010 in Präparation)
2. Goldschmidt, H., Moehler T. Multiple Myeloma, Springer 2010 (in Präparation)
3. Peest, D., Goldschmidt, H. Multiples Myelom. Deutscher Ärzte-Verlag Köln 2010 (in Präparation)